Retrieve available abstracts of 391 articles: HTML format
Single Articles
June 2025
PORTACCIO E, Betti M, De Meo E, Pasto L, et al Age-dependent response to initial highly effective treatment in relapsing
multiple sclerosis.
Mult Scler. 2025 Jun 19:13524585251345317. doi: 10.1177/13524585251345317. PubMedAbstract available
ARAB BAFRANI M, Rios V, Kim MJ, Balan A, et al Gynecological health: A missing link in comprehensive treatment monitoring for
multiple sclerosis.
Mult Scler. 2025 Jun 18:13524585251346371. doi: 10.1177/13524585251346371. PubMedAbstract available
SAHU M, Chomba M, Mortel D, Braun S, et al Factors associated with delay to diagnosis of multiple sclerosis in Zambia.
Mult Scler. 2025 Jun 17:13524585251344832. doi: 10.1177/13524585251344832. PubMedAbstract available
BEREK K, Schmidauer M, Bsteh G, Auer M, et al Kappa free light chain index predicts long-term disease activity and disability
accrual in multiple sclerosis.
Mult Scler. 2025 Jun 16:13524585251344807. doi: 10.1177/13524585251344807. PubMedAbstract available
STEIN C, O'Keeffe F, Brosnan M, Flynn C, et al Cognitive reserve in multiple sclerosis: The role of depression and fatigue.
Mult Scler. 2025 Jun 11:13524585251338757. doi: 10.1177/13524585251338757. PubMedAbstract available
MOCCIA M Clinical commentary to gender-affirming interventions and prognosis in multiple
sclerosis.
Mult Scler. 2025 Jun 3:13524585251341177. doi: 10.1177/13524585251341177. PubMed
NEYAL N, Nathoo N, Cathcart-Rake EJ, Kantarci OH, et al Gender-affirming interventions and prognosis in multiple sclerosis.
Mult Scler. 2025 Jun 3:13524585251341174. doi: 10.1177/13524585251341174. PubMedAbstract available
VARLEY J, Beyrouti R, Nicholas R, Dorsey R, et al A comparison of JC virus assay performance provided with originator and
biosimilar natalizumab.
Mult Scler. 2025;31:882-885. PubMedAbstract available
VUKUSIC S, Hubben F, Gavoille A, Malek Y, et al Beyond the switch to the biosimilar of natalizumab: What is the impact of
changing the JCV test?
Mult Scler. 2025;31:877-881. PubMedAbstract available
GARTHOF S, Schafer S, Elmers J, Schwed L, et al Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech
metrics using a multi-speech-task protocol in a cross-sectional MS cohort study.
Mult Scler. 2025;31:856-865. PubMedAbstract available
LEAVITT VM, Fox R, Mostert J, D'Haeseleer M, et al Cognitive test performance and disease progression in primary and secondary
progressive MS: An analysis of the SPRINT-MS study.
Mult Scler. 2025;31:866-876. PubMedAbstract available
ARNOLD DL, Kolind S, Assemlal HE, Bar-Or A, et al Short- and long-term effects of early versus delayed treatment with ocrelizumab
on cerebellar volume loss in patients with RMS and PPMS.
Mult Scler. 2025;31:821-832. PubMedAbstract available
May 2025
NOVAKOVA L, Rosenstein I, Axelsson M, Schoonheim MM, et al Plateau of practice effects and noise with repeat SDMT testing and in multiple
sclerosis.
Mult Scler. 2025 May 31:13524585251344794. doi: 10.1177/13524585251344794. PubMedAbstract available
VILASECA A, Vidal-Jordana A, Sceppacuercia S, Calderon W, et al Radiologically isolated syndrome: How could we accurately diagnose a subclinical
period of multiple sclerosis?
Mult Scler. 2025 May 30:13524585251332115. doi: 10.1177/13524585251332115. PubMedAbstract available
FOONG YC, Butzkueven H Should disease-modifying therapy be discontinued in older patients with stable
multiple sclerosis after long-term clinical and radiological stability? - No.
Mult Scler. 2025 May 26:13524585251344805. doi: 10.1177/13524585251344805. PubMed
ROD BE, Hogestol EA, Torkildsen O, Bjornevik K, et al Comparative effectiveness of rituximab and cladribine in relapsing-remitting
multiple sclerosis: A target trial emulation.
Mult Scler. 2025 May 26:13524585251342727. doi: 10.1177/13524585251342727. PubMedAbstract available
ROSTON S, Quick MH, Tisavipat N, Rattanathamsakul N, et al Assessment of increased opening pressure in patients with multiple sclerosis and
aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder.
Mult Scler. 2025 May 26:13524585251340841. doi: 10.1177/13524585251340841. PubMedAbstract available
ZANE GK, Sutton A, Brumwell A, Hossain MR, et al The path to prevention of multiple sclerosis: Considerations for Epstein-Barr
virus vaccine-based prevention studies.
Mult Scler. 2025 May 26:13524585251340812. doi: 10.1177/13524585251340812. PubMedAbstract available
MARRIE RA, Maxwell CJ, Everett K, Zhu F, et al Health care use preceding pediatric multiple sclerosis: A population-based study
from Ontario, Canada.
Mult Scler. 2025 May 23:13524585251338745. doi: 10.1177/13524585251338745. PubMedAbstract available
MACCARRONE D, Prados F, Ciccarelli O The relationship between cladribine and reduced regional grey matter volume loss
in people with relapsing-remitting multiple sclerosis.
Mult Scler. 2025 May 3:13524585251338772. doi: 10.1177/13524585251338772. PubMed
LOREFICE L, Zivadinov R Treating comorbidities in multiple sclerosis is disease-modifying: Yes.
Mult Scler. 2025 May 3:13524585251338750. doi: 10.1177/13524585251338750. PubMed
GRESELIN M, Lu PJ, Mroczek M, Cerda-Fuertes N, et al AI-assisted identification of disability patterns within identical EDSS grades.
Mult Scler. 2025;31:677-688. PubMedAbstract available
FOX RJ, Cohan S, Mao-Draayer Y, Weinstock-Guttman B, et al Safety and tolerability of conversion to siponimod from other disease-modifying
therapies in patients with advancing forms of relapsing MS: Results from the
EXCHANGE study.
Mult Scler. 2025;31:706-718. PubMedAbstract available
LEE A, Iordanova RT, Smith JB, Li BH, et al Incidence and prevalence of neuromyelitis optica spectrum disorder in a
contemporary, multi-ethnic cohort.
Mult Scler. 2025;31:642-657. PubMedAbstract available
CHAN F, Berhanu D, Samadzadeh S, Francis A, et al Smoking status and vascular risk factors as predictors of disability in
AQP4-NMOSD and MOGAD.
Mult Scler. 2025;31:658-667. PubMedAbstract available
April 2025
YALDIZLI O, Benkert P, Achtnichts L, Bar-Or A, et al Personalized treatment decision algorithms for the clinical application of serum
neurofilament light chain in multiple sclerosis: A modified Delphi Study.
Mult Scler. 2025 Apr 28:13524585251335466. doi: 10.1177/13524585251335466. PubMedAbstract available
STEPHENS S, Iseyas N, Yeh EA Physical activity demonstrates protective associations with structural visual
metrics in children with multiple sclerosis through time.
Mult Scler. 2025 Apr 28:13524585251335510. doi: 10.1177/13524585251335510. PubMedAbstract available
PILOTTO S, Pontieri L, Nielsen HH, Rasmussen PV, et al Pediatric Onset Multiple Sclerosis (POMS): Exploring phenotypic characterization
and pubertal influences in modulating the disease activity from the Danish MS
Registry (DMSR).
Mult Scler. 2025 Apr 28:13524585251335476. doi: 10.1177/13524585251335476. PubMedAbstract available
MADILL E, Moreira Ferreira V, Healy B, Zurawski J, et al Change in serum neurofilament light chain and glial fibrillary acidic protein
levels with high-efficacy and low-efficacy early therapy in multiple sclerosis.
Mult Scler. 2025 Apr 28:13524585251335521. doi: 10.1177/13524585251335521. PubMedAbstract available
FERRAZZANO G, Maccarrone D, Guerra A, Collura A, et al The effects of gamma-tACS on cognitive impairment in multiple sclerosis: A
randomized, double-blind, sham-controlled, pilot study.
Mult Scler. 2025 Apr 26:13524585251333575. doi: 10.1177/13524585251333575. PubMedAbstract available
GREENWALD MA, Cancel Asencio HG, Dwyer J, Moss A, et al Differential Validity in the Written, Oral, and Electronic SDMT in Multiple
Sclerosis.
Mult Scler. 2025 Apr 24:13524585251330961. doi: 10.1177/13524585251330961. PubMedAbstract available
KRAJNC N, Fottinger F, Ponleitner M, Kornek B, et al Diagnostic accuracy of inter-eye difference of ganglion cell layer alone in
identifying optic neuritis in multiple sclerosis.
Mult Scler. 2025 Apr 22:13524585251332895. doi: 10.1177/13524585251332895. PubMedAbstract available
MARRIE RA, Bolton JM, Ling V, Bernstein CN, et al Risk factors for incident peripartum mental illness in multiple sclerosis.
Mult Scler. 2025 Apr 18:13524585251330109. doi: 10.1177/13524585251330109. PubMedAbstract available
MACARON G, Farah N, Charbonneau S, Morrow SA, et al Addressing patient-reported cognitive impairment in multiple sclerosis clinical
practice: A challenging endeavor.
Mult Scler. 2025 Apr 18:13524585251334488. doi: 10.1177/13524585251334488. PubMedAbstract available
FADLALLAH Y, Wang Y, Malik MT, Tian F, et al Frequency and potential risk factors associated with the development of
asymptomatic T2 hyperintense cervical spine lesions on MRI in patients with
relapsing-remitting multiple sclerosis.
Mult Scler. 2025 Apr 17:13524585251331405. doi: 10.1177/13524585251331405. PubMedAbstract available
JENSEN MP, Robles S, Nash MG, May S, et al Hypnosis and mindfulness audio recordings for reducing fatigue in individuals
with multiple sclerosis: A randomized controlled study.
Mult Scler. 2025 Apr 17:13524585251329820. doi: 10.1177/13524585251329820. PubMedAbstract available
EL AYOUBI NK, Bal MN, Metri N, El Sammak S, et al Slower retinal thinning over a year predicts continuous NEDA status at follow-up
in multiple sclerosis: A longitudinal OCT study.
Mult Scler. 2025 Apr 12:13524585251332499. doi: 10.1177/13524585251332499. PubMedAbstract available
BSTEH G, Hegen H, Albrecht P, Havla J, et al Emphasizing complementary in "Investigating the complementary value of OCT to MRI
in cognitive impairment in relapsing-remitting multiple sclerosis".
Mult Scler. 2025 Apr 12:13524585251329800. doi: 10.1177/13524585251329800. PubMed
CHRISTENSEN R, Jolly A, Yam C, Yiannakas MC, et al Response to letter to the editor: 'Investigating the complementary value of OCT
to MRI in cognitive impairment in relapsing-remitting multiple sclerosis'.
Mult Scler. 2025 Apr 12:13524585251329787. doi: 10.1177/13524585251329787. PubMed
LIU X, Wang Y, Wei N, Zhu W, et al The characteristics and influencing factors of paramagnetic rim lesions in
Chinese MS patients: A 7T MRI study.
Mult Scler. 2025 Apr 12:13524585251328902. doi: 10.1177/13524585251328902. PubMedAbstract available
REVIE L, Jurjens A, Eveslage M, Trumpelmann S, et al Suboptimal B-cell depletion is associated with progression independent of relapse
activity in multiple sclerosis patients treated with ocrelizumab.
Mult Scler. 2025 Apr 3:13524585251329849. doi: 10.1177/13524585251329849. PubMedAbstract available
SAYLOR D, Rijke N, McDonell J, Laurson-Doube J, et al Recommendations for essential medicines for multiple sclerosis in low-resource
settings.
Mult Scler. 2025;31:464-473. PubMedAbstract available
BARANZINI SE The Barancik award lecture: Multi-disciplinary research will be the key to stop,
restore, and end MS.
Mult Scler. 2025;31:384-391. PubMedAbstract available
MERLO D, Ja J, Foong YC, Zhu C, et al Long-term acceptability of MSReactor digital cognitive monitoring among people
living with multiple sclerosis.
Mult Scler. 2025 Apr 1:13524585251329035. doi: 10.1177/13524585251329035. PubMedAbstract available
BOBELNA B, Lobjois Q, Croitoru S, Jalkh E, et al Incidence of optic neuritis among Afro-descendant, a cohort study.
Mult Scler. 2025;31:529-538. PubMedAbstract available
BUDHRAM A, Flanagan EP Testing for myelin oligodendrocyte glycoprotein antibodies: Who, what, where,
when, why, and how.
Mult Scler. 2025;31:505-511. PubMedAbstract available
SONI RH, Garcia M, Oak E, Applbaum EJ, et al Acute eculizumab treatment in a pediatric patient with AQP4-IgG+ NMOSD.
Mult Scler. 2025;31:612-614. PubMedAbstract available
TOMMASO G, Damiano P, Pietro I Eculizumab treatment during pregnancy in a patient with AQP4-IgG-seropositive
NMOSD: A case report.
Mult Scler. 2025;31:615-617. PubMedAbstract available
LAAKSO SM, Oh J, Raufdeen F, Jones A, et al Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic
implications from a multicenter cohort.
Mult Scler. 2025;31:607-611. PubMedAbstract available
March 2025
CIAMPI E, Garcia L, Carcamo C, Soler B, et al Practical issues concerning the use of optical coherence tomography in multiple
sclerosis in Latin America: Discussion from 19 centres on behalf of the Foro
Latam EM study group.
Mult Scler. 2025 Mar 29:13524585251329159. doi: 10.1177/13524585251329159. PubMedAbstract available
LEVIT E, Cohen I, Mahajan A, Ulano A, et al Evaluation of the relationship between brainstem lesions and apnea hypopnea index
in patients with multiple sclerosis.
Mult Scler. 2025 Mar 29:13524585251327875. doi: 10.1177/13524585251327875. PubMedAbstract available
NOROOZI R, Tsai HH, Yu K, Bronson P, et al Metabolic and lipid alterations in multiple sclerosis linked to disease severity.
Mult Scler. 2025 Mar 27:13524585251325468. doi: 10.1177/13524585251325468. PubMedAbstract available
LIU X, Zhang C Longitudinal investigation of neuroimaging changes related to memory decline in
multiple sclerosis: Testing a mechanistic model.
Mult Scler. 2025 Mar 27:13524585251324854. doi: 10.1177/13524585251324854. PubMed
SIMANI L, Leavitt VM Response to the letter: Longitudinal investigation of neuroimaging changes
related to memory decline in multiple sclerosis: Testing a mechanistic model.
Mult Scler. 2025 Mar 27:13524585251324872. doi: 10.1177/13524585251324872. PubMed
BAKIRTZIS C, Dimitriou N, Moysiadis T, El-Wahsh S, et al Communication deficits in multiple sclerosis: Interactions with cognitive
dysfunction and their impact on employment status.
Mult Scler. 2025 Mar 20:13524585251328556. doi: 10.1177/13524585251328556. PubMedAbstract available
FREEDMAN DE, Oh J, Meza C, Feinstein A, et al Seizure history and cognitive dysfunction in people with multiple sclerosis.
Mult Scler. 2025 Mar 18:13524585251326841. doi: 10.1177/13524585251326841. PubMedAbstract available
WILLIAMS J, Marin WM, Wade KJ, Suseno R, et al Copy number variation at the complement C4 locus is associated with risk for
multiple sclerosis.
Mult Scler. 2025 Mar 15:13524585251324850. doi: 10.1177/13524585251324850. PubMedAbstract available
CAROLUS B, Dequirez PL, Olivier L, Hafez S, et al Short- and mid-term efficacy of sacral neuromodulation in the treatment of
neurogenic overactive bladder in patients with multiple sclerosis.
Mult Scler. 2025 Mar 13:13524585251323178. doi: 10.1177/13524585251323178. PubMedAbstract available
CARVAJAL R, Tur C, Borras-Bermejo B, Saylor D, et al Vaccination in multiple sclerosis: Tackling challenges and paving the way for
effective immunization.
Mult Scler. 2025 Mar 12:13524585251318513. doi: 10.1177/13524585251318513. PubMedAbstract available
MAILLART E, Rollot F, Leray E, Benyahya L, et al Pregnancy and birth outcomes in women with multiple sclerosis: Comparison of the
RESPONSE study to the general French population.
Mult Scler. 2025;31:324-337. PubMedAbstract available
ZEYDAN B, Son J, Neyal N, Schwarz CG, et al Upper cervical spinal cord atrophy in MS: Sex, menopause, and neurodegeneration.
Mult Scler. 2025;31:278-289. PubMedAbstract available
LEBRUN-FRENAY C The confavreux lecture: The radiologically isolated syndrome diagnosis, prognosis
and perspectives.
Mult Scler. 2025;31:249-256. PubMedAbstract available
AL GBURI M, Mazzola M, Absinta M, Gaitan MI, et al Paramagnetic rim lesion formation is predicted by the initial
gadolinium-enhancing lesion diameter.
Mult Scler. 2025;31:263-277. PubMedAbstract available
RAMDANI R, Pique J, Deschamps R, Ciron J, et al Evaluation of the predictive value of CSF-restricted oligoclonal bands on
residual disability and risk of relapse in adult patients with MOGAD: MOGADOC
study.
Mult Scler. 2025;31:290-302. PubMedAbstract available
February 2025
STOGBAUER J, Schegerer V, Berger FK, Schulz-Schaeffer W, et al Severe coxsackie virus B5 encephalitis mimics autoimmune limbic encephalitis in a
young woman under long-term B-cell depletion with ocrelizumab: A case report.
Mult Scler. 2025 Feb 27:13524585251322327. doi: 10.1177/13524585251322327. PubMedAbstract available
BALSHI A Climate change and multiple sclerosis: Clinical challenges and strategies.
Mult Scler. 2025 Feb 26:13524585251322664. doi: 10.1177/13524585251322664. PubMedAbstract available
GOGA JJ, Ginell KM, Ng YT, Ehde DM, et al Feasibility, reliability, and validity of ambulatory smartphone-administered
cognitive tests in multiple sclerosis.
Mult Scler. 2025 Feb 25:13524585251320814. doi: 10.1177/13524585251320814. PubMedAbstract available
BARRANTES-CEPAS M, Noteboom S, Colato E, Battaglini M, et al Treatment effects of cladribine tablets on data-driven patterns of regional grey
matter atrophy in multiple sclerosis.
Mult Scler. 2025 Feb 25:13524585251314779. doi: 10.1177/13524585251314779. PubMedAbstract available
DELUCA J An interdisciplinary approach is necessary in the treatment of cognitive decline
in Multiple Sclerosis: Commentary.
Mult Scler. 2025 Feb 25:13524585251315357. doi: 10.1177/13524585251315357. PubMed
DONKERS SJ, Walker LA An interdisciplinary approach is necessary in the treatment of cognitive decline
in multiple sclerosis - YES.
Mult Scler. 2025 Feb 25:13524585251315344. doi: 10.1177/13524585251315344. PubMed
SCHOEPS VA, Smith JB, Langer-Gould A Migraines, the multiple sclerosis prodrome, and multiple sclerosis
susceptibility.
Mult Scler. 2025 Feb 19:13524585251318293. doi: 10.1177/13524585251318293. PubMedAbstract available
LINDBERG S, Sandgren S, Axelsson M, Rosenstein I, et al Quality of life is decreased in persons with relapsing-remitting multiple
sclerosis experiencing progression independent of relapse activity.
Mult Scler. 2025 Feb 18:13524585251318516. doi: 10.1177/13524585251318516. PubMedAbstract available
KARATSIDIS A, Angelini L, Scaramozza M, Bartholome E, et al Characterizing gait in people with multiple sclerosis using digital data from
smartphone sensors: A proposed framework.
Mult Scler. 2025 Feb 18:13524585251316242. doi: 10.1177/13524585251316242. PubMedAbstract available
MITRACHE DESAGA AC, Noui Y, Silfverberg T, Carlson K, et al Patient-reported outcomes of quality of life before and after autologous
hematopoietic stem cell transplantation for multiple sclerosis.
Mult Scler. 2025 Feb 17:13524585251315363. doi: 10.1177/13524585251315363. PubMedAbstract available
SIMONSEN CS, Flemmen HO, Broch L, Brekke K, et al Reduced childbirth rates in multiple sclerosis from the prodromal phase: Evidence
from a population-based cohort study.
Mult Scler. 2025 Feb 17:13524585251315077. doi: 10.1177/13524585251315077. PubMedAbstract available
VAVASOUR I, Elliott C, Arnold DL, Gaetano L, et al Presence of slowly expanding lesions in multiple sclerosis predicts progressive
demyelination within lesions and normal-appearing tissue over time.
Mult Scler. 2025 Feb 14:13524585251316519. doi: 10.1177/13524585251316519. PubMedAbstract available
ALBERGONI M, Preziosa P, Meani A, Dallari C, et al Aerobic capacity moderates the association between cervical cord atrophy and
clinical disability in mildly disabled multiple sclerosis patients.
Mult Scler. 2025 Feb 14:13524585251318647. doi: 10.1177/13524585251318647. PubMedAbstract available
MARRODAN M, Sao Aviles A, Rio J, Cobo-Calvo A, et al Performance of treatment response scoring systems among patients with multiple
sclerosis treated with high-efficacy therapies.
Mult Scler. 2025 Feb 10:13524585251316471. doi: 10.1177/13524585251316471. PubMedAbstract available
VILASECA A, Tintore M, Carbonell-Mirabent P, Rodriguez-Barranco M, et al Uncovering alternative diagnoses in patients with clinical syndromes suggestive
of multiple sclerosis: A transversal study from the prospective Barcelona CIS
cohort.
Mult Scler. 2025 Feb 5:13524585251314749. doi: 10.1177/13524585251314749. PubMedAbstract available
SUMOWSKI JF, Sandry J Multiple Sclerosis Cognitive Scale (MSCS): A brief psychometrically robust metric
of patient-reported cognitive difficulty.
Mult Scler. 2025 Feb 2:13524585241309805. doi: 10.1177/13524585241309805. PubMedAbstract available
TAUL-MADSEN L, Hvid LG, Riis H, Brolos MK, et al A head-to-head comparison of the effects of aerobic versus resistance training on
physical capacity and physical function in people with multiple sclerosis:
Results from the MSBOOST trial.
Mult Scler. 2025;31:174-183. PubMedAbstract available
CACCIAGUERRA L, Storelli L, Pagani E, Preziosa P, et al Use of brain MRI and gene expression atlases to reconstruct the pathophysiology
of autoimmune neurological disorders: The proof-of-concept of NMOSD.
Mult Scler. 2025;31:140-158. PubMedAbstract available
CORBOY JR, Fox RJ, Cutter G, Engebretson E, et al DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension
trial.
Mult Scler. 2025;31:159-173. PubMedAbstract available
LEBRUN-FRENAY C, Kerbrat S, Okuda DT, Landes-Chateau C, et al Analysis of healthcare utilization before the diagnosis of radiologically
isolated syndrome.
Mult Scler. 2025;31:184-196. PubMedAbstract available
PATEL AD, Connors A, Esch ME Ofatumumab-associated colitis: A case report.
Mult Scler. 2025;31:242-245. PubMedAbstract available
January 2025
MARTIRE MS, Moiola L, Maggi P, Borrelli S, et al Reliability of paramagnetic rim lesion detection at 1.5T MRI in multiple
sclerosis patients.
Mult Scler. 2025 Jan 31:13524585251314358. doi: 10.1177/13524585251314358. PubMedAbstract available
ACHIRON A, Warszawer Y, Nissan Y, Kerpel A, et al Positive impact of cladribine tablets on reducing brain atrophy in patients with
relapsing-remitting multiple sclerosis: A longitudinal study.
Mult Scler. 2025 Jan 27:13524585251313749. doi: 10.1177/13524585251313749. PubMedAbstract available
DE ANGELIS F, Ammoscato F, Parker RA, Plantone D, et al Neurofilament heavy chain in secondary progressive multiple sclerosis.
Mult Scler. 2025 Jan 22:13524585241311212. doi: 10.1177/13524585241311212. PubMedAbstract available
VARLEY JA, Davies NW Opportunistic enteroviral infections in MS patients treated with anti-CD20
therapies.
Mult Scler. 2025 Jan 20:13524585241310395. doi: 10.1177/13524585241310395. PubMed
YILMAZER C, D'haeseleer M, Soler B, Van Wijmeersch B, et al Assessing pain in multiple sclerosis: Test-retest reliability of patient-reported
outcome measures and accuracy of screening tools.
Mult Scler. 2025 Jan 16:13524585241310139. doi: 10.1177/13524585241310139. PubMedAbstract available
DEL CANTO A, Carcamo C, Garcia L, Aylwin E, et al Real-world evidence of ocrelizumab in Chilean patients with multiple sclerosis.
Mult Scler. 2025 Jan 6:13524585241309835. doi: 10.1177/13524585241309835. PubMedAbstract available
WITT L, Dost-Kovalsky K, Friedmann N, Bast N, et al Ofatumumab-exposed breastfeeding in multiple sclerosis patients.
Mult Scler. 2025 Jan 6:13524585241307165. doi: 10.1177/13524585241307165. PubMedAbstract available
SALTER A, Lancia S, Cutter GR, Fox RJ, et al Post-acute sequela of COVID-19 infection in individuals with multiple sclerosis.
Mult Scler. 2025 Jan 3:13524585241310104. doi: 10.1177/13524585241310104. PubMedAbstract available
SIMANI L, Tozlu C, Lee S, Dworkin J, et al Longitudinal investigation of neuroimaging changes related to memory decline in
multiple sclerosis: Testing a mechanistic model.
Mult Scler. 2025 Jan 3:13524585241303491. doi: 10.1177/13524585241303491. PubMedAbstract available
GIOVANNONI G, Boyko A, Correale J, Edan G, et al Long-term follow-up of patients with a first clinical demyelinating event
(clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS:
Findings for the ORACLE-MS cohort.
Mult Scler. 2025;31:44-58. PubMedAbstract available
MANISCALCO GT, Dinoto A, Foglia MC, Di Battista ME, et al Epstein-Barr virus infection in patients with MOGAD.
Mult Scler. 2025;31:117-120. PubMedAbstract available
CARNERO CONTENTTI E, Rotstein D, Okuda DT, Paul F, et al How to avoid missing a diagnosis of neuromyelitis optica spectrum disorder.
Mult Scler. 2025;31:8-22. PubMedAbstract available
December 2024
MAGGI G, Altieri M, Risi M, Rippa V, et al Cognitive reserve predicts long-term cognitive trajectories in
relapsing-remitting multiple sclerosis.
Mult Scler. 2024 Dec 27:13524585241302167. doi: 10.1177/13524585241302167. PubMedAbstract available
BRIGGS FB, Conway DS, Hersh CM, Fitzgerald KC, et al The onset presentation of multiple sclerosis differs in Hispanic/Latinx Americans
compared with non-Hispanic White Americans.
Mult Scler. 2024 Dec 24:13524585241304976. doi: 10.1177/13524585241304976. PubMedAbstract available
CHRISTENSEN R, Jolly A, Yam C, Yiannakas MC, et al Investigating the complementary value of OCT to MRI in cognitive impairment in
relapsing-remitting multiple sclerosis.
Mult Scler. 2024 Dec 20:13524585241304356. doi: 10.1177/13524585241304356. PubMedAbstract available
MALLUCCI G, Zimmer A, Sfikas N, Cerda-Fuertes N, et al Neurostatus-SMARTCARE clinical trial: Enabling health care professionals to
assess EDSS for decentralized trials in multiple sclerosis.
Mult Scler. 2024 Dec 20:13524585241305966. doi: 10.1177/13524585241305966. PubMedAbstract available
CORREALE J, Marrodan M Live-attenuated vaccines for multiple sclerosis patients living in regions with
endemic infections: A complex decision.
Mult Scler. 2024 Dec 18:13524585241305956. doi: 10.1177/13524585241305956. PubMedAbstract available
NYLANDER A, Sisodia N, Henderson K, Wijangco J, et al From "invisible" to "audible": Features extracted during simple speech tasks
classify patient-reported fatigue in multiple sclerosis.
Mult Scler. 2024 Dec 17:13524585241303855. doi: 10.1177/13524585241303855. PubMedAbstract available
VAN DAM M, Rottgering JG, Nauta IM, de Jong BA, et al Understanding the complex network of objectively assessed cognition and
self-reported psychological symptoms in people with multiple sclerosis.
Mult Scler. 2024 Dec 9:13524585241302173. doi: 10.1177/13524585241302173. PubMedAbstract available
KRYSKO KM Considerations for family planning in adolescent and young adults with multiple
sclerosis.
Mult Scler. 2024 Dec 7:13524585241303481. doi: 10.1177/13524585241303481. PubMed
CHANG G, Stoney S, Narula S Pregnancy outcomes in adolescent and young adult patients with multiple
sclerosis: A case series.
Mult Scler. 2024 Dec 7:13524585241303490. doi: 10.1177/13524585241303490. PubMedAbstract available
FRAMKE E, Sellebjerg F, Kant M, Stilund M, et al Risk of hypertension in patients with multiple sclerosis treated with
teriflunomide compared to dimethyl fumarate: A nationwide cohort study in
Denmark.
Mult Scler. 2024 Dec 4:13524585241299715. doi: 10.1177/13524585241299715. PubMedAbstract available
CARVAJAL R, Rodriguez-Acevedo B, Garcia-Vasco L, Zabalza A, et al Secondary organising pneumonia associated to COVID-19 infection in patients with
central nervous system inflammatory demyelinating diseases treated with anti-CD20
therapies.
Mult Scler. 2024;30:1788-1801. PubMedAbstract available
KEVER A, Heuer LB, Simani L, Leavitt VM, et al Development and initial validation of the Cognitive Change Scale (CCS).
Mult Scler. 2024;30:1815-1824. PubMedAbstract available
JIANG X, McGinley M, Johnston J, Alberts J, et al A digital version of the nine-hole peg test: Speed may be a more reliable measure
of upper-limb disability than completion time in patients with multiple
sclerosis.
Mult Scler. 2024 Dec 1:13524585241301854. doi: 10.1177/13524585241301854. PubMedAbstract available
CHITNIS T, Arnold DL, Quartier P, Chirieac M, et al Safety, efficacy, and tolerability of alemtuzumab in pediatric patients with
active relapsing-remitting multiple sclerosis: The LemKids study.
Mult Scler. 2024 Dec 1:13524585241295554. doi: 10.1177/13524585241295554. PubMedAbstract available
PORTACCIO E Toward a holistic approach to multiple sclerosis: The role of social determinants
of health.
Mult Scler. 2024 Dec 1:13524585241302684. doi: 10.1177/13524585241302684. PubMed
LEFORT M, Dejardin O, Berger E, Camdessanche JP, et al Association between education level and access to disease-modifying treatment in
patients with multiple sclerosis in France.
Mult Scler. 2024 Dec 1:13524585241289276. doi: 10.1177/13524585241289276. PubMedAbstract available
GAITAN MI, Marquez RV, Ayerbe J, Reich DS, et al Imaging Outcomes for Phase 2 Trials Targeting Compartmentalized Inflammation.
Mult Scler. 2024;30. PubMedAbstract available
MOTL RW Randomized Controlled Trials of Rehabilitation in Multiple Sclerosis: Barriers
and Unmet Needs.
Mult Scler. 2024;30. PubMedAbstract available
PILUTTI LA, Donkers SJ Exercise as a Therapeutic Intervention in Multiple Sclerosis.
Mult Scler. 2024;30. PubMedAbstract available
MCGINLEY MP Improving Access to MS Care Through Technology.
Mult Scler. 2024;30. PubMedAbstract available
BERGSLAND N, Dwyer MG, Zivadinov R Imaging the Choroid Plexus.
Mult Scler. 2024;30. PubMedAbstract available
LANGER-GOULD A Racial and Ethnic Disease Phenotype Differences Are Driven by Genetics: No.
Mult Scler. 2024;30. PubMedAbstract available
KOCH MW, Camara-Lemarroy C, Strijbis E, Mostert J, et al Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design
Considerations for Phase 2 Clinical Trials in Progressive MS.
Mult Scler. 2024;30. PubMedAbstract available
ONTANEDA D, Miron VE Breaking Barriers in Multiple Sclerosis.
Mult Scler. 2024;30. PubMed
November 2024
LEFORT M, Dejardin O, Berger E, Camdessanche JP, et al Association between education level and disability progression in patients with
multiple sclerosis in France.
Mult Scler. 2024 Nov 30:13524585241289274. doi: 10.1177/13524585241289274. PubMedAbstract available
KALAITZIDIS G, Ezzedin O, Bacchetti A, Moussa H, et al Homonymous hemi-macular atrophy in multiple sclerosis.
Mult Scler. 2024 Nov 23:13524585241297816. doi: 10.1177/13524585241297816. PubMedAbstract available
GANS A, Verrengia EP, Ricchiuti E, Leva S, et al Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis:
Two case reports and comprehensive literature review.
Mult Scler. 2024 Nov 21:13524585241295677. doi: 10.1177/13524585241295677. PubMedAbstract available
DARVISHI S, Donnachie E, Gasperi C, Hapfelmeier A, et al Vaccination as a risk factor for pediatric multiple sclerosis: Insights from a
retrospective case-control study.
Mult Scler. 2024 Nov 14:13524585241297003. doi: 10.1177/13524585241297003. PubMedAbstract available
MAGGI P, Absinta M Emerging MRI biomarkers for the diagnosis of multiple sclerosis.
Mult Scler. 2024 Nov 7:13524585241293579. doi: 10.1177/13524585241293579. PubMedAbstract available
HOFFMAN EM, Brown L, Jolliffe E, Sechi E, et al McArdle sign and neck flexion-induced change in central motor conduction in
multiple sclerosis.
Mult Scler. 2024 Nov 6:13524585241295868. doi: 10.1177/13524585241295868. PubMedAbstract available
WITT L, Haben S, Dost-Kovalsky K, Friedmann N, et al Impact of symptomatic multiple sclerosis therapy on pregnancy outcome.
Mult Scler. 2024 Nov 6:13524585241293363. doi: 10.1177/13524585241293363. PubMedAbstract available
HOCHSTETLER A, Lehtinen MK Choroid plexus as a mediator of CNS inflammation in multiple sclerosis.
Mult Scler. 2024 Nov 6:13524585241292974. doi: 10.1177/13524585241292974. PubMedAbstract available
JIANG Y, Cesta CE, Liu Q, Kingwell E, et al Exploring the relationship between polycystic ovarian syndrome, testosterone, and
multiple sclerosis in women: A nationwide cohort study and genome-wide
cross-trait analysis.
Mult Scler. 2024 Nov 6:13524585241292802. doi: 10.1177/13524585241292802. PubMedAbstract available
TOOROP AA, Wessels MH, Boonkamp L, Gelissen LM, et al Serum neurofilament light and glial fibrillary acidic protein levels are not
associated with wearing-off symptoms in natalizumab-treated multiple sclerosis
patients.
Mult Scler. 2024 Nov 4:13524585241293940. doi: 10.1177/13524585241293940. PubMedAbstract available
HSU S, Balan A, Bove R Topical review: Lactation and use of DMTs in women with MS.
Mult Scler. 2024;30:1578-1591. PubMedAbstract available
NOVI G, Sbragia E, Benedetti L, Schenone A, et al Relapsing meningitis and limbic encephalitis in anti-AQP4-Ab-associated
neuromyelitis optica spectrum disorder.
Mult Scler. 2024;30:1692-1696. PubMedAbstract available
October 2024
YOUNG CA, Rog DJ, Sharrack B, Tanasescu R, et al Physical and psychological aspects of multiple sclerosis: Revisiting the Multiple
Sclerosis Impact Scale (MSIS-29).
Mult Scler. 2024 Oct 30:13524585241288393. doi: 10.1177/13524585241288393. PubMedAbstract available
TREABA CA, Herranz E, Barletta VT, Mehndiratta A, et al Phenotyping in vivo chronic inflammation in multiple sclerosis by combined
(11)C-PBR28 MR-PET and 7T susceptibility-weighted imaging.
Mult Scler. 2024 Oct 22:13524585241284157. doi: 10.1177/13524585241284157. PubMedAbstract available
Erratum to "Ofatumumab-induced severe reactivation of psoriasis in a patient with
multiple sclerosis" Multiple Sclerosis Journal; 2024: 30(8); 1086-1088. DOI:
10.1177/13524585241260564.
Mult Scler. 2024 Oct 22:13524585241290986. doi: 10.1177/13524585241290986. PubMed
PALLADINO R, Chataway J, Mathew M, Majeed A, et al Trajectories and management of vascular risk following the diagnosis of multiple
sclerosis: A population-based matched cohort study between 1987 and 2018 in
England.
Mult Scler. 2024 Oct 17:13524585241287388. doi: 10.1177/13524585241287388. PubMedAbstract available
DE NADAI AS, Zamora RJ, Finch A, Miller DM, et al Multiple sclerosis subgroups: Data-driven clusters based on patient-reported
outcomes and a large clinical sample.
Mult Scler. 2024 Oct 17:13524585241282763. doi: 10.1177/13524585241282763. PubMedAbstract available
VAN LIEROP ZY, Wessels MH, Lekranty WM, Moraal B, et al Impact of serum neurofilament light on clinical decisions in a tertiary multiple
sclerosis clinic.
Mult Scler. 2024 Oct 17:13524585241277044. doi: 10.1177/13524585241277044. PubMedAbstract available
VLAD B, Neidhart S, Hilty M, Asplund Hogelin K, et al Intrathecal immune reactivity against Measles-, Rubella-, and Varicella Zoster
viruses is associated with cerebrospinal fluid inflammation in multiple
sclerosis.
Mult Scler. 2024 Oct 8:13524585241279645. doi: 10.1177/13524585241279645. PubMedAbstract available
AMEZCUA L, Hamilton RH, Ciccarelli O The current state of diversity, equity, and inclusion in multiple sclerosis
research, clinical trials, and workforce.
Mult Scler. 2024 Oct 8:13524585241286988. doi: 10.1177/13524585241286988. PubMed
VERCELLINO M, Marasciulo S, Ricotti E, Rolando A, et al Long-term modifications of the peripheral immune repertoire after switching from
sequestering disease-modifying treatments in multiple sclerosis.
Mult Scler. 2024 Oct 7:13524585241284846. doi: 10.1177/13524585241284846. PubMedAbstract available
LEE S, Marrie RA, Fadda G, Freedman MS, et al Is there a prodrome to NMOSD? An investigation of neurologic symptoms preceding
the first NMOSD attack.
Mult Scler. 2024;30. PubMedAbstract available
September 2024
NESBITT C, Van Der Walt A, Butzkueven H, Devitt B, et al Multiple sclerosis and cancer: Navigating a dual diagnosis.
Mult Scler. 2024 Sep 30:13524585241274523. doi: 10.1177/13524585241274523. PubMedAbstract available
BAYOUMI A, Hasan KM, Thomas JA, Yazdani A, et al Glymphatic dysfunction in multiple sclerosis and its association with disease
pathology and disability.
Mult Scler. 2024 Sep 29:13524585241280842. doi: 10.1177/13524585241280842. PubMedAbstract available
OCAMPO A, Hatami F, Cuklina J, Graham G, et al Prognostic factors for worsening and improvement in multiple sclerosis using a
multistate model.
Mult Scler. 2024 Sep 28:13524585241275471. doi: 10.1177/13524585241275471. PubMedAbstract available
INOJOSA H, Voigt I, Wenk J, Ferber D, et al Integrating large language models in care, research, and education in multiple
sclerosis management.
Mult Scler. 2024 Sep 23:13524585241277376. doi: 10.1177/13524585241277376. PubMedAbstract available
JACOBS BM, Schalk L, Tregaskis-Daniels E, Tank P, et al The relationship between ethnicity and multiple sclerosis characteristics in the
United Kingdom: A UK MS Register study.
Mult Scler. 2024 Sep 20:13524585241277018. doi: 10.1177/13524585241277018. PubMedAbstract available
O'DONNELL E, Schuette A, Waltz M, Aaen G, et al Patient and family views on research priorities and design of clinical trials and
research studies in pediatric multiple sclerosis.
Mult Scler. 2024 Sep 17:13524585241274580. doi: 10.1177/13524585241274580. PubMedAbstract available
PILLONI G, Lustberg M, Malik M, Feinberg C, et al Hand functioning in progressive multiple sclerosis improves with tDCS added to
daily exercises: A home-based randomized, double-blinded, sham-controlled
clinical trial.
Mult Scler. 2024 Sep 13:13524585241275013. doi: 10.1177/13524585241275013. PubMedAbstract available
LANDI D, Bartolomeo S, Bovis F, Amato MP, et al Maternal and fetal outcomes in an Italian multicentric cohort of women with
multiple sclerosis exposed to dimethyl fumarate during pregnancy.
Mult Scler. 2024 Sep 12:13524585241274600. doi: 10.1177/13524585241274600. PubMedAbstract available
HOLTZER R, Foley FW, Motl RW, Wagshul ME, et al Brain hemodynamic responses and fall prediction in older adults with multiple
sclerosis.
Mult Scler. 2024 Sep 11:13524585241277400. doi: 10.1177/13524585241277400. PubMedAbstract available
PIEDRABUENA MA, Correale J, Farez MF, Rodriguez Murua S, et al Telomere length as a biomarker in multiple sclerosis.
Mult Scler. 2024 Sep 9:13524585241273054. doi: 10.1177/13524585241273054. PubMedAbstract available
LUNEMANN JD, Sao Aviles A, Tintore M, Midaglia L, et al Cytomegalovirus immune responses are associated with lower serum NfL and
disability accumulation risk at multiple sclerosis onset.
Mult Scler. 2024 Sep 9:13524585241274571. doi: 10.1177/13524585241274571. PubMedAbstract available
ZURRER WE, Cannon AE, Ilchenko D, Gaitan MI, et al Misdiagnosis and underdiagnosis of multiple sclerosis: A systematic review and
meta-analysis.
Mult Scler. 2024 Sep 8:13524585241274527. doi: 10.1177/13524585241274527. PubMedAbstract available
SARTHOU A, Chretien P, Giorgi L, Chiron A, et al The kappa free light chains index is an accurate diagnostic biomarker for
paediatric multiple sclerosis.
Mult Scler. 2024 Sep 8:13524585241274034. doi: 10.1177/13524585241274034. PubMedAbstract available
COERVER EM, Kacar S, Ciccarelli O, Sormani MP, et al Aging is associated with reduced inflammatory disease activity independent of
disease duration in relapsing multiple sclerosis trial populations.
Mult Scler. 2024 Sep 8:13524585241272938. doi: 10.1177/13524585241272938. PubMedAbstract available
BRIGGS FB, Gunzler DD, Miller DM, Ontaneda D, et al Mobility trajectories in multiple sclerosis: A comparative study of timed 25-foot
walk and a patient-reported outcome measure.
Mult Scler. 2024 Sep 5:13524585241274607. doi: 10.1177/13524585241274607. PubMedAbstract available
PETRACCA M, Ruggieri S, Nistri R, Tomasso I, et al Brain reserve and timing of clinical onset in multiple sclerosis.
Mult Scler. 2024 Sep 5:13524585241272046. doi: 10.1177/13524585241272046. PubMedAbstract available
TOLJAN K, Daboul L, Raza P, Martin ML, et al Diagnostic performance of central vein sign versus oligoclonal bands for multiple
sclerosis.
Mult Scler. 2024 Sep 5:13524585241271988. doi: 10.1177/13524585241271988. PubMedAbstract available
LANDES-CHATEAU C, Ricigliano VA, Mondot L, Thouvenot E, et al Choroid plexus enlargement correlates with periventricular pathology but not with
disease activity in radiologically isolated syndrome.
Mult Scler. 2024;30:1278-1289. PubMedAbstract available
CHICO-GARCIA JL, Sainz Amo R, Monreal E, Sainz de la Maza S, et al Progression independent of relapse activity can be predicted by passively
acquired tapping speed through a smartphone for 1 month: A prospective study.
Mult Scler. 2024;30:1341-1349. PubMedAbstract available
ROTSTEIN DL, Freedman MS, Konig A, Lee L, et al Investigation of health care use and a possible prodrome before the first attack
in NMOSD and MOGAD.
Mult Scler. 2024;30:1331-1340. PubMedAbstract available
COBO-CALVO A, Tintore M Prioritizing global strategies to cure MS.
Mult Scler. 2024;30:1239-1241. PubMed
ABBATEMARCO JR, Aboseif A, Swetlik C, Widmar J, et al Neighborhood disadvantage, race, and clinical outcomes in neuromyelitis optica
spectrum disorder.
Mult Scler. 2024;30:1322-1330. PubMedAbstract available
KRUPP L, O'Neill KA Monitoring cognitive functioning in MS will trigger anxiety in patients: Yes.
Mult Scler. 2024;30:1252-1254. PubMed
KLEIN M Monitoring cognitive functioning in MS will trigger anxiety in patients: No.
Mult Scler. 2024;30:1254-1256. PubMed
August 2024
BEBO BF JR, Banwell BL, Whitacre CC, Coetzee T, et al The refined Pathways to Cures Research Roadmap for multiple sclerosis cures.
Mult Scler. 2024 Aug 30:13524585241266483. doi: 10.1177/13524585241266483. PubMedAbstract available
ZICCARDI S, Guandalini M, Fuchs TA, Calabrese M, et al The time to include cognition in the multiple sclerosis concept of progression
independent from relapse activity is now.
Mult Scler. 2024 Aug 28:13524585241264476. doi: 10.1177/13524585241264476. PubMedAbstract available
FUCHS TA, Schoonheim MM, Zivadinov R, Dwyer MG, et al Cognitive progression independent of relapse in multiple sclerosis.
Mult Scler. 2024 Aug 28:13524585241256540. doi: 10.1177/13524585241256540. PubMedAbstract available
TUR C, Portaccio E Progression independent of relapse activity in multiple sclerosis: Time to
account for cognitive decline.
Mult Scler. 2024 Aug 28:13524585241273037. doi: 10.1177/13524585241273037. PubMed
RIVERO-DE-AGUILAR A, Perez-Rios M, Mascarenas-Garcia M, Ruano-Ravina A, et al Discrepancies in the results reported for multiple sclerosis clinical trials: A
comparison between ClinicalTrials.gov and peer-reviewed journals.
Mult Scler. 2024 Aug 27:13524585241273089. doi: 10.1177/13524585241273089. PubMedAbstract available
CICCARESE G, Zanghi A, Herzum A, Fidanzi C, et al Acute urticaria following ofatumumab injection for multiple sclerosis.
Mult Scler. 2024 Aug 26:13524585241273084. doi: 10.1177/13524585241273084. PubMed
HARROUD A, Sawcer SJ, Baranzini SE Genetics of multiple sclerosis severity: The importance of statistical power in
replication studies.
Mult Scler. 2024 Aug 14:13524585241264472. doi: 10.1177/13524585241264472. PubMed
MONTOBBIO N, Carmisciano L, Signori A, Ponzano M, et al Creating an automated tool for a consistent and repeatable evaluation of
disability progression in clinical studies for multiple sclerosis.
Mult Scler. 2024 Aug 14:13524585241243157. doi: 10.1177/13524585241243157. PubMedAbstract available
LAPUCCI C, Frau J, Cocco E, Coghe G, et al Ocrelizumab in MS patients with persistence of disease activity after
alemtuzumab: A multi-center Italian study.
Mult Scler. 2024 Aug 14:13524585241266509. doi: 10.1177/13524585241266509. PubMedAbstract available
KALINCIK T The era of harmonised disability outcomes in multiple sclerosis.
Mult Scler. 2024 Aug 14:13524585241266517. doi: 10.1177/13524585241266517. PubMed
CAMPAGNA MP, Lechner-Scott J, Taylor BV, Havrdova EK, et al Re: Genetics of multiple sclerosis severity: The importance of statistical power
in replication studies and Re: From discovery to replication: Power and
definitions matter for multiple sclerosis severity.
Mult Scler. 2024 Aug 14:13524585241264469. doi: 10.1177/13524585241264469. PubMed
BSTEH G, Hegen H, Krajnc N, Fottinger F, et al Retinal layer thinning for monitoring disease-modifying treatment in relapsing
multiple sclerosis-Evidence for applying a rebaselining concept.
Mult Scler. 2024 Aug 7:13524585241267257. doi: 10.1177/13524585241267257. PubMedAbstract available
CAMPBELL JA, Simpson-Yap S, Taylor BV, van der Mei I, et al Significantly increasing multiple sclerosis prevalence in Australia from 2010 to
2021.
Mult Scler. 2024 Aug 5:13524585241265890. doi: 10.1177/13524585241265890. PubMedAbstract available
CAMERON MH, Hildebrand A, Hugos C, Wooliscroft L, et al A walking aid selection, training, and education program (ADSTEP) to prevent
falls in multiple sclerosis: A randomized controlled trial.
Mult Scler. 2024 Aug 5:13524585241265031. doi: 10.1177/13524585241265031. PubMedAbstract available
DVORAK E, Levy S, Anderson JR, Sumowski JF, et al Phonemic processing is below expectations and linked to word-finding difficulty
in multiple sclerosis.
Mult Scler. 2024 Aug 5:13524585241259648. doi: 10.1177/13524585241259648. PubMedAbstract available
ROOS I, Sharmin S, Malpas C, Ozakbas S, et al Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and
alemtuzumab in relapsing-remitting multiple sclerosis.
Mult Scler. 2024 Aug 1:13524585241267211. doi: 10.1177/13524585241267211. PubMedAbstract available
VOSKUHL R All women with multiple sclerosis should start hormone replacement therapy at
menopause unless contraindicated: Yes.
Mult Scler. 2024;30:1107-1109. PubMed
ZHANG Q, Noyce AJ, Robson J, Giovannoni G, et al No association between oral contraceptive exposure and subsequent MS: A
population-based nested case-control study in primary care.
Mult Scler. 2024;30:1221-1226. PubMedAbstract available
CHEEMA S, Matharu M Facial pain in MS: When to think of trigeminal autonomic cephalalgia.
Mult Scler. 2024;30:1230-1231. PubMed
July 2024
BEBO B, Coetzee T, Gray E, Helme A, et al The first global landscape analysis of multiple sclerosis research funding.
Mult Scler. 2024 Jul 31:13524585241265961. doi: 10.1177/13524585241265961. PubMedAbstract available
PROSPERINI L, Ruggieri S, Haggiag S, Tortorella C, et al Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the
real-world context.
Mult Scler. 2024 Jul 31:13524585241266180. doi: 10.1177/13524585241266180. PubMedAbstract available
ROMOZZI M, Vollono C, Calabresi P, Iorio R, et al Epilepsia Partialis Continua as a manifestation of aquaporin-4 autoimmunity.
Mult Scler. 2024 Jul 30:13524585241261535. doi: 10.1177/13524585241261535. PubMedAbstract available
CARNERO CONTENTTI E Expanding the spectrum of NMOSD: New cases of autoimmune epilepsy and
meningoencephalitis.
Mult Scler. 2024 Jul 30:13524585241261545. doi: 10.1177/13524585241261545. PubMed
SIDHU NK, Proudfoot H, Adan HM, Fawson S, et al Diversity and inclusion in behavioural intervention trials in multiple sclerosis:
A commentary.
Mult Scler. 2024 Jul 26:13524585241248279. doi: 10.1177/13524585241248279. PubMed
STRIDH P, Huang J, Kockum I From discovery to replication: Power and definitions matter for multiple
sclerosis severity.
Mult Scler. 2024 Jul 26:13524585241265021. doi: 10.1177/13524585241265021. PubMed
MOHAN SD, Peterson S, Brenton JN, Carmichael SL, et al Association of nutritional intake with clinical and imaging activity in pediatric
multiple sclerosis.
Mult Scler. 2024;30:1056-1065. PubMedAbstract available
ZEINEDDINE M, Al-Roughani R, Farouk Ahmed S, Khoury S, et al Safety and effectiveness of disease-modifying therapies after switching from
natalizumab.
Mult Scler. 2024;30:1026-1035. PubMedAbstract available
UZAWA A, Mori M, Masuda H, Muto M, et al Contributions of CSF interleukin-6 elevation to the pathogenesis of myelin
oligodendrocyte glycoprotein antibody-associated disease.
Mult Scler. 2024;30:977-982. PubMedAbstract available
DE JONG DJ, Strijbis EM, Killestein J Information from ecological momentary assessments lead to over-medicalization:
Commentary.
Mult Scler. 2024;30:972-973. PubMed
PREZIOSA P, Rocca MA, Filippi M Information from ecological momentary assessments leads to over-medicalization:
No.
Mult Scler. 2024;30:970-972. PubMed
HOGESTOL EA, Berg-Hansen P Information from ecological momentary assessments lead to over-medicalization:
Yes.
Mult Scler. 2024;30:968-969. PubMed
LEVIT E, Ren Z, Gonzenbach V, Azevedo CJ, et al Choroid plexus volume differentiates MS from its mimics.
Mult Scler. 2024;30:1072-1076. PubMedAbstract available
MEALLI F, Mattei A, Mariottini A, Massacesi L, et al Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly
natalizumab administration: A post hoc analysis of the REFINE study.
Mult Scler. 2024;30:1077-1080. PubMedAbstract available
COBAN H Tick-borne illnesses in patients treated with B-cell depleting agents:
Considerations for neurologists.
Mult Scler. 2024;30:1084-1085. PubMed
MCMURRAN CE, Mukherjee T, Brown JWL, Coles AJ, et al Bexarotene leads to durable improvements in visual evoked potential latency: A
follow-up study of the Cambridge Centre for Myelin Repair One trial.
Mult Scler. 2024;30:1066-1071. PubMedAbstract available
June 2024
MOROZUMI T, Preziosa P, Meani A, Pessina G, et al Brain and cervical spinal cord MRI correlates of sensorimotor impairment in
patients with multiple sclerosis.
Mult Scler. 2024 Jun 24:13524585241260145. doi: 10.1177/13524585241260145. PubMedAbstract available
MALLUCCI G, Monti MC, Ponzio M, Borrelli P, et al Impact of multiple sclerosis comorbidities on quality of life and job activity.
Mult Scler. 2024 Jun 24:13524585241260550. doi: 10.1177/13524585241260550. PubMedAbstract available
SCARAMOZZA M, Chiesa PA, Zajac L, Sun Z, et al Konectom cognitive processing speed test enables reliable remote, unsupervised
cognitive assessment in people with multiple sclerosis: Exploring the use of
substitution time as a novel digital outcome measure.
Mult Scler. 2024 Jun 24:13524585241259650. doi: 10.1177/13524585241259650. PubMedAbstract available
MAGYARI M All women with multiple sclerosis should start hormone replacement therapy at
menopause unless contraindicated: No.
Mult Scler. 2024 Jun 22:13524585241254987. doi: 10.1177/13524585241254987. PubMed
PETHERAM K, Dobson R All women with multiple sclerosis should start hormone replacement therapy at
menopause unless contraindicated: Commentary.
Mult Scler. 2024 Jun 22:13524585241254989. doi: 10.1177/13524585241254989. PubMed
CONTE WL Addressing LGBTQ+ health equity and disparities in multiple sclerosis: A call for
research and action.
Mult Scler. 2024 Jun 19:13524585241263281. doi: 10.1177/13524585241263281. PubMedAbstract available
MORROW SA, Hancock L Monitoring cognitive functioning in multiple sclerosis will trigger anxiety in
patients: Commentary.
Mult Scler. 2024 Jun 16:13524585241261200. doi: 10.1177/13524585241261200. PubMed
BALSHI A, Manning N, Dempsey J, Kumbar S, et al Altered lymphocyte profiles and herpes zoster infections in patients with
multiple sclerosis on natalizumab.
Mult Scler. 2024 Jun 16:13524585241260537. doi: 10.1177/13524585241260537. PubMedAbstract available
KOLSCHE T, Willison AG, Meuth SG, Pawlitzki M, et al Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple
sclerosis.
Mult Scler. 2024 Jun 15:13524585241260564. doi: 10.1177/13524585241260564. PubMed
DALLA COSTA G, Leocani L, Pisa M, Croese T, et al Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody
titres.
Mult Scler. 2024 Jun 14:13524585241260977. doi: 10.1177/13524585241260977. PubMedAbstract available
KRIJNEN EA, Kouwenhoven RM, Noteboom S, Barkhof F, et al Subtypes and location of (juxta)cortical lesions relate to cognitive dysfunction
in people with multiple sclerosis.
Mult Scler. 2024 Jun 13:13524585241260968. doi: 10.1177/13524585241260968. PubMedAbstract available
SMETS I, Versteegh M, Huygens S, Wokke B, et al Benefits of early highly effective versus escalation treatment strategies in
relapsing multiple sclerosis estimated using a treatment-sequence model.
Mult Scler. 2024 Jun 10:13524585241258692. doi: 10.1177/13524585241258692. PubMedAbstract available
NOVA A, Di Caprio G, Bernardinelli L, Fazia T, et al Genetic and early life factors influence on time-to-multiple sclerosis diagnosis:
A UK Biobank study.
Mult Scler. 2024 Jun 7:13524585241257205. doi: 10.1177/13524585241257205. PubMedAbstract available
BORRELLI S, Guisset F, Vanden Bulcke C, Stolting A, et al Enlarged perivascular spaces are associated with brain microangiopathy and aging
in multiple sclerosis.
Mult Scler. 2024 Jun 7:13524585241256881. doi: 10.1177/13524585241256881. PubMedAbstract available
PONZANO M, Signori A, Bellavia A, Carbone A, et al Race and ethnicity in multiple sclerosis phase 3 clinical trials: A systematic
review.
Mult Scler. 2024 Jun 7:13524585241254283. doi: 10.1177/13524585241254283. PubMedAbstract available
FOSTER MA, Prados F, Collorone S, Kanber B, et al Improving explanation of motor disability with diffusion-based graph metrics at
onset of the first demyelinating event.
Mult Scler. 2024;30:800-811. PubMedAbstract available
MONTOBBIO N, Bovis F, Signori A, Ponzano M, et al Therapeutic lag: Is treatment effect delayed in progressive MS?
Mult Scler. 2024;30:843-846. PubMedAbstract available
PFEUFFER S Psoriasisform dermatitis following anti-CD20 therapies: Immunologic lessons and
management dilemmas.
Mult Scler. 2024;30:897-898. PubMed
May 2024
AKBARIAN F, Rossi C, Costers L, D'hooghe MB, et al Stimulus-related modulation in the 1/f spectral slope suggests an impaired
inhibition during a working memory task in people with multiple sclerosis.
Mult Scler. 2024 May 20:13524585241253777. doi: 10.1177/13524585241253777. PubMedAbstract available
MENG D, Sacco R, Disanto G, Widmer F, et al Memory B cell-guided extended interval dosing of ocrelizumab in multiple
sclerosis.
Mult Scler. 2024 May 20:13524585241250199. doi: 10.1177/13524585241250199. PubMedAbstract available
LEBRUN-FRENAY C, Okuda DT Time to move past typical syndromes in the diagnosis of multiple sclerosis.
Mult Scler. 2024 May 15:13524585241253519. doi: 10.1177/13524585241253519. PubMed
WICKLEIN R, Kreitner L, Wild A, Aly L, et al Retinal small vessel pathology is associated with disease burden in multiple
sclerosis.
Mult Scler. 2024 May 15:13524585241247775. doi: 10.1177/13524585241247775. PubMedAbstract available
NAIZER H, Wozny J, Krause TM, Huson E, et al Trends in central nervous system-active polypharmacy among people with multiple
sclerosis.
Mult Scler. 2024 May 15:13524585241251986. doi: 10.1177/13524585241251986. PubMedAbstract available
HEWARD KD, Roy-Hewitson C, Solomon AJ Multiple sclerosis presenting with paroxysmal symptoms: Patients at the
limitations of current diagnostic criteria.
Mult Scler. 2024 May 15:13524585241253513. doi: 10.1177/13524585241253513. PubMedAbstract available
COLLORONE S, Coll L, Lorenzi M, Llado X, et al Artificial intelligence applied to MRI data to tackle key challenges in multiple
sclerosis.
Mult Scler. 2024 May 13:13524585241249422. doi: 10.1177/13524585241249422. PubMedAbstract available
DAGNEW B, Laslett LL, Honan CA, Blizzard L, et al The association of comorbidities with sleep quality among Australians with
multiple sclerosis: Insights from the Australian Multiple Sclerosis Longitudinal
Study.
Mult Scler. 2024 May 13:13524585241248278. doi: 10.1177/13524585241248278. PubMedAbstract available
ANDERSEN ML, Jolving LR, Iachina M, Stenager E, et al Children born preterm or small for gestational age to mothers with multiple
sclerosis: Do these children have an increased risk of infections in early life?
Mult Scler. 2024 May 8:13524585241249077. doi: 10.1177/13524585241249077. PubMedAbstract available
PROSPERINI L, Haggiag S Late-onset multiple sclerosis from a different angle.
Mult Scler. 2024 May 8:13524585241249901. doi: 10.1177/13524585241249901. PubMed
PORTACCIO E, Grossi P, Bellomi F, Bianchi V, et al Meaningful cognitive change for the Minimal Assessment of Cognitive Function in
Multiple Sclerosis.
Mult Scler. 2024 May 8:13524585241249084. doi: 10.1177/13524585241249084. PubMedAbstract available
April 2024
FEINSTEIN A Depression is a core symptom of multiple sclerosis.
Mult Scler. 2024 Apr 30:13524585241245637. doi: 10.1177/13524585241245637. PubMed
HANCOCK LM Depression is a core symptom of multiple sclerosis: Yes.
Mult Scler. 2024 Apr 30:13524585241249564. doi: 10.1177/13524585241249564. PubMed
LEAVITT VM Depression is a core symptom of multiple sclerosis: NO.
Mult Scler. 2024 Apr 30:13524585241245653. doi: 10.1177/13524585241245653. PubMed
MANUEL AM, Gottlieb A, Freeman L, Zhao Z, et al Montelukast as a repurposable additive drug for standard-efficacy multiple
sclerosis treatment: Emulating clinical trials with retrospective administrative
health claims data.
Mult Scler. 2024 Apr 25:13524585241240398. doi: 10.1177/13524585241240398. PubMedAbstract available
BIANCHI A, Cortese R, Prados F, Tur C, et al Optic chiasm involvement in multiple sclerosis, aquaporin-4 antibody-positive
neuromyelitis optica spectrum disorder and myelin oligodendrocyte
glycoprotein-associated disease.
Mult Scler. 2024 Apr 22:13524585241240420. doi: 10.1177/13524585241240420. PubMedAbstract available
NOVAK F, Bajwa HM, Ostergaard K, Berg JM, et al Extended interval dosing with ocrelizumab in multiple sclerosis.
Mult Scler. 2024 Apr 22:13524585241245296. doi: 10.1177/13524585241245296. PubMedAbstract available
OKUDA DT, Lebrun-Frenay C Radiologically isolated syndrome in the spectrum of multiple sclerosis.
Mult Scler. 2024 Apr 15:13524585241245306. doi: 10.1177/13524585241245306. PubMedAbstract available
CHITNIS T, Banwell B, Kappos L, Arnold DL, et al Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label
extension of TERIKIDS.
Mult Scler. 2024 Apr 15:13524585241242050. doi: 10.1177/13524585241242050. PubMedAbstract available
HEMOND CC, Solomon AJ Multiple sclerosis can be diagnosed solely with dissemination in space: No.
Mult Scler. 2024 Apr 14:13524585241245297. doi: 10.1177/13524585241245297. PubMed
MCGINLEY MP, Cohen JA Multiple sclerosis can be diagnosed solely with dissemination in space:
Commentary.
Mult Scler. 2024 Apr 14:13524585241245319. doi: 10.1177/13524585241245319. PubMed
TOOSY AT, Barkhof F Multiple sclerosis can be diagnosed solely with dissemination in space: Yes.
Mult Scler. 2024 Apr 14:13524585241245313. doi: 10.1177/13524585241245313. PubMed
OZTURK B, Taskiran E, Demir S, Tuncer MA, et al Prevalence and incidence of multiple sclerosis in Turkey: A nationwide
epidemiologic study.
Mult Scler. 2024 Apr 14:13524585241245318. doi: 10.1177/13524585241245318. PubMedAbstract available
SCHNEIDER M, Kramer J, Banks A, Moses H, et al New onset lymphopenia in patients with relapsing multiple sclerosis switching
from long-standing dimethyl fumarate treatment to diroximel fumarate: A case
series.
Mult Scler. 2024 Apr 11:13524585241242027. doi: 10.1177/13524585241242027. PubMedAbstract available
MOCCIA M, Terracciano D, Brescia Morra V, Castaldo G, et al Neurofilament in clinical practice: Is the multiple sclerosis community ready?
Mult Scler. 2024 Apr 11:13524585241246536. doi: 10.1177/13524585241246536. PubMed
KWON S, Han KD, Jung JH, Cho EB, et al Risk of depression and anxiety in multiple sclerosis and neuromyelitis optica
spectrum disorder: A nationwide cohort study in South Korea.
Mult Scler. 2024 Apr 1:13524585241237093. doi: 10.1177/13524585241237093. PubMedAbstract available
ALOISI F, Salvetti M EBV infection drives MS pathology: Yes.
Mult Scler. 2024;30. PubMed
CORTESE M, Ascherio A EBV infection drives MS pathology: Commentary.
Mult Scler. 2024;30. PubMed
'T HART BA, van Luijn MM EBV infection drives MS pathology: No.
Mult Scler. 2024;30. PubMed
TUR C, Battiston M, Yiannakas MC, Collorone S, et al What contributes to disability in progressive MS? A brain and cervical
cord-matched quantitative MRI study.
Mult Scler. 2024;30. PubMedAbstract available
REEVES JA, Mohebbi M, Wicks T, Salman F, et al Paramagnetic rim lesions predict greater long-term relapse rates and clinical
progression over 10 years.
Mult Scler. 2024;30. PubMedAbstract available
KLISTORNER S, Barnett MH, Wang C, Parratt J, et al Longitudinal enlargement of choroid plexus is associated with chronic lesion
expansion and neurodegeneration in RRMS patients.
Mult Scler. 2024;30. PubMedAbstract available
SBRAGIA E, Boffa G, Varaldo R, Raiola AM, et al An aggressive form of MOGAD treated with aHSCT: A case report.
Mult Scler. 2024;30. PubMedAbstract available
March 2024
PAPPOLLA A, Auger C, Sao-Aviles A, Tur C, et al Prediction of disease activity and treatment failure in relapsing-remitting MS
patients initiating daily oral DMTs.
Mult Scler. 2024 Mar 29:13524585241240653. doi: 10.1177/13524585241240653. PubMedAbstract available
SIMPSON AC, Hu C, Mowry EM, Naismith RT, et al Structural MRI measures are associated with fatigue severity and persistence in a
large, real-world cohort of people with multiple sclerosis.
Mult Scler. 2024 Mar 25:13524585241239473. doi: 10.1177/13524585241239473. PubMedAbstract available
SORENSEN PS, Bramow S, Magyari M, Werdelin L, et al Torben Fog - A Danish pioneer in a multi-faceted spectrum of multiple sclerosis
research.
Mult Scler. 2024 Mar 24:13524585241239506. doi: 10.1177/13524585241239506. PubMedAbstract available
MAILLART E, Redolfi S, Louapre C, Houot M, et al Clinical correlates of respiratory disorders in patients with severe multiple
sclerosis: A cross-sectional cohort.
Mult Scler. 2024 Mar 22:13524585241238840. doi: 10.1177/13524585241238840. PubMedAbstract available
CAMPAGNA MP, Havrdova EK, Horakova D, Izquierdo G, et al No evidence for association between rs10191329 severity locus and longitudinal
disease severity in 1813 relapse-onset multiple sclerosis patients from the
MSBase registry.
Mult Scler. 2024 Mar 21:13524585241240406. doi: 10.1177/13524585241240406. PubMedAbstract available
HJALGRIM H, Rostgaard K Infectious mononucleosis and risk of multiple sclerosis: Proxy or culprit?
Mult Scler. 2024 Mar 21:13524585241237708. doi: 10.1177/13524585241237708. PubMed
GOLDACRE R Risk of multiple sclerosis in individuals with infectious mononucleosis: a
national population-based cohort study using hospital records in England,
2003-2023.
Mult Scler. 2024 Mar 21:13524585241237707. doi: 10.1177/13524585241237707. PubMedAbstract available
JOHNSSON M, Stenberg YT, Farman HH, Blennow K, et al Serum neurofilament light for detecting disease activity in individual patients
in multiple sclerosis: A 48-week prospective single-center study.
Mult Scler. 2024 Mar 13:13524585241237388. doi: 10.1177/13524585241237388. PubMedAbstract available
NAKAMURA K, Sun Z, Hara-Cleaver C, Bodhinathan K, et al Natalizumab reduces loss of gray matter and thalamic volume in patients with
relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized,
placebo-controlled AFFIRM trial.
Mult Scler. 2024 Mar 12:13524585241235055. doi: 10.1177/13524585241235055. PubMedAbstract available
EHLING R, Seebacher B, Brenneis C Letter to the editor: Mobile health interventions in multiple sclerosis: A
systematic review.
Mult Scler. 2024 Mar 11:13524585241234789. doi: 10.1177/13524585241234789. PubMed
HILLERT J, Bove R, Haddad LB, Hellwig K, et al Expert opinion on the use of contraception in people with multiple sclerosis.
Mult Scler. 2024 Mar 8:13524585241228103. doi: 10.1177/13524585241228103. PubMedAbstract available
APREA MG, Schiavetti I, Portaccio E, Ballerini C, et al Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple
sclerosis.
Mult Scler. 2024 Mar 8:13524585241232266. doi: 10.1177/13524585241232266. PubMedAbstract available
KUBICKI K, Stefoski D Iatrogenic myelodysplastic syndrome complicating multiple sclerosis: A case
report.
Mult Scler. 2024 Mar 8:13524585241235539. doi: 10.1177/13524585241235539. PubMedAbstract available
MONTALBAN X, Piasecka-Stryczynska K, Kuhle J, Benkert P, et al Efficacy and safety results after >3.5 years of treatment with the Bruton's
tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term
follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid
sub-study.
Mult Scler. 2024 Mar 4:13524585241234783. doi: 10.1177/13524585241234783. PubMedAbstract available
GIULIANI G, Zilli C, Caramia F, Di Piero V, et al SUNCT syndrome secondary to multiple sclerosis: Not only trigeminal neuralgia.
Mult Scler. 2024 Mar 1:13524585241235535. doi: 10.1177/13524585241235535. PubMedAbstract available
ROCCHI C, Forcadela M, Kelly P, Linaker S, et al The absence of antibodies in longitudinally extensive transverse myelitis may
predict a more favourable prognosis.
Mult Scler. 2024;30:345-356. PubMedAbstract available
February 2024
AFZAL RM, Romme Christensen J, Gynthersen RMM, Lebech AM, et al Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis:
A case report.
Mult Scler. 2024 Feb 29:13524585241235542. doi: 10.1177/13524585241235542. PubMedAbstract available
KARI S, Bucciarelli F, Angles T, Oster AC, et al Increased levels of circulating soluble CD226 in multiple sclerosis.
Mult Scler. 2024 Feb 29:13524585241234489. doi: 10.1177/13524585241234489. PubMedAbstract available
HEESEN C, Luhmann D Reply: Mobile health interventions in multiple sclerosis: A systematic review.
Mult Scler. 2024 Feb 29:13524585241234777. doi: 10.1177/13524585241234777. PubMed
LIM TRU, Kumaran SP, Suthiphosuwan S, Espiritu AI, et al Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity
in multiple sclerosis.
Mult Scler. 2024 Feb 28:13524585241228426. doi: 10.1177/13524585241228426. PubMedAbstract available
NAKKEN O, Aarseth JH, Wergeland S, Stigum H, et al BCG vaccination and multiple sclerosis risk: A Norwegian cohort study.
Mult Scler. 2024 Feb 27:13524585241230440. doi: 10.1177/13524585241230440. PubMedAbstract available
MILLER AE Dissemination in time as a requirement for diagnosis of multiple sclerosis: Time
for a change?
Mult Scler. 2024 Feb 27:13524585241233999. doi: 10.1177/13524585241233999. PubMedAbstract available
KRIEGER SC, Sinks S, Huang F, Steverson J, et al The impact of social distancing measures on anti-JC virus serostatus changes
before and during the COVID-19 pandemic in US patients with multiple sclerosis.
Mult Scler. 2024 Feb 26:13524585241232274. doi: 10.1177/13524585241232274. PubMedAbstract available
BOAVENTURA M, Sastre-Garriga J, Rimkus CM, Rovira A, et al T1/T2-weighted ratio: A feasible MRI biomarker in multiple sclerosis.
Mult Scler. 2024 Feb 22:13524585241233448. doi: 10.1177/13524585241233448. PubMedAbstract available
EMMA C, Vesela P, Kay P, Huseyin H, et al Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple
sclerosis: Case report and literature review.
Mult Scler. 2024 Feb 22:13524585241232277. doi: 10.1177/13524585241232277. PubMedAbstract available
ERCAN MB, Kocer B, Altiparmak T, Arslan I, et al Responsiveness to pembrolizumab in severe early-onset natalizumab associated
PML-IRIS in patient with relapsing-remitting multiple sclerosis.
Mult Scler. 2024 Feb 22:13524585241231655. doi: 10.1177/13524585241231655. PubMed
JALALEDDINI K, Bermel RA, Talente B, Weinstein D, et al A US payer perspective health economic model assessing value of monitoring
disease activity to inform discontinuation and re-initiation of DMT in multiple
sclerosis.
Mult Scler. 2024 Feb 19:13524585241227372. doi: 10.1177/13524585241227372. PubMedAbstract available
ROCCA MA, D'Amore G, Valsasina P, Tedone N, et al 2.5-Year changes of connectivity dynamism are relevant for physical and cognitive
deterioration in multiple sclerosis.
Mult Scler. 2024 Feb 19:13524585241231155. doi: 10.1177/13524585241231155. PubMedAbstract available
ROVARIS M, Toselli E, Mendozzi L, Di Tella S, et al Eye movement desensitization and reprocessing for depressed individuals with
multiple sclerosis: A pilot study.
Mult Scler. 2024 Feb 19:13524585241230236. doi: 10.1177/13524585241230236. PubMedAbstract available
HOANG P, Sturnieks DL, Butler A, Chaplin C, et al A custom-built step exergame training programme to prevent falls in people with
multiple sclerosis: A multicentre randomised controlled trial.
Mult Scler. 2024 Feb 16:13524585241229360. doi: 10.1177/13524585241229360. PubMedAbstract available
COLLONGUES N, Durand-Dubief F, Lebrun-Frenay C, Audoin B, et al Cancer and multiple sclerosis: 2023 recommendations from the French Multiple
Sclerosis Society.
Mult Scler. 2024 Feb 15:13524585231223880. doi: 10.1177/13524585231223880. PubMedAbstract available
PATEL S, Rafferty S, Aquino L, Chadha S, et al VISIBL-MS: A bilingual educational framework to increase awareness of early
multiple sclerosis.
Mult Scler. 2024 Feb 15:13524585241228739. doi: 10.1177/13524585241228739. PubMedAbstract available
KVISTAD CE, Lehmann AK, Kvistad SAS, Holmoy T, et al Autologous hematopoietic stem cell transplantation for multiple sclerosis:
Long-term follow-up data from Norway.
Mult Scler. 2024 Feb 12:13524585241231665. doi: 10.1177/13524585241231665. PubMedAbstract available
MOTL RW, Russell DI, Pilutti LA, Metse AP, et al Drop-out, adherence, and compliance in randomized controlled trials of exercise
training in multiple sclerosis: Short report.
Mult Scler. 2024 Feb 9:13524585241229332. doi: 10.1177/13524585241229332. PubMedAbstract available
BELLUCCI G, Buscarinu MC, Renie R, Rinaldi V, et al Disentangling multiple sclerosis phenotypes through Mendelian disorders: A
network approach.
Mult Scler. 2024 Feb 9:13524585241227119. doi: 10.1177/13524585241227119. PubMedAbstract available
ZIAEI A, Solomon O, Casper TC, Waltz M, et al Gene-environment interactions: Epstein-Barr virus infection and risk of
pediatric-onset multiple sclerosis.
Mult Scler. 2024 Feb 9:13524585231224685. doi: 10.1177/13524585231224685. PubMedAbstract available
GILMARTIN CG, Hoyle N, Garjani A, Dixon T, et al Real-world data on siponimod-related lymphopenia among people with secondary
progressive multiple sclerosis.
Mult Scler. 2024 Feb 7:13524585231225711. doi: 10.1177/13524585231225711. PubMedAbstract available
MCGINLEY MP, Manouchehrinia A The landscape of multiple sclerosis registries: Strengths and limitations.
Mult Scler. 2024 Feb 6:13524585241228746. doi: 10.1177/13524585241228746. PubMed
VUKUSIC S, Bourre B, Casey R, Deiva K, et al The Response Study: A French registry on pregnancy in women with MS and related
disorders and their children up to 6 years-Protocol, recruitment status, and
baseline characteristics.
Mult Scler. 2024;30:216-226. PubMedAbstract available
GHAJARZADEH M, Fitzgerald KC, Mowry EM, Nourbakhsh B, et al Association between demographics, socioeconomics, and disease-related factors and
the perception of stigma in people with MS.
Mult Scler. 2024;30:238-246. PubMedAbstract available
SCHNEIDER R, Brand-Arzamendi K, Reynold Lim T, Lee LE, et al Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim
lesions in people with radiologically isolated syndrome.
Mult Scler. 2024;30:156-165. PubMedAbstract available
GONZALEZ CALDITO N, Graham EL, Grebenciucova E Rituximab and pregnancy: Late-onset neutropenia in a 2-month infant whose mother
received rituximab 2 weeks prior to childbirth.
Mult Scler. 2024;30:272-274. PubMedAbstract available
LANGDON D Neuropsychological assessment in MS is outdated and in need for innovation: NO.
Mult Scler. 2024;30:152-153. PubMed
January 2024
NAKAMURA K, Thoomukuntla B, Bena J, Cohen JA, et al Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.
Mult Scler. 2024 Jan 29:13524585231224702. doi: 10.1177/13524585231224702. PubMedAbstract available
SWITAL M, Drouin J, Miranda S, Bakchine S, et al Use of multiple sclerosis disease-modifying therapies during pregnancy in France:
Nationwide study between 2010 and 2021.
Mult Scler. 2024 Jan 27:13524585231223395. doi: 10.1177/13524585231223395. PubMedAbstract available
MISCIOSCIA A, Treaba CA, Barletta VT, Herranz E, et al White matter paramagnetic rim and non-rim lesions share a periventricular
gradient in multiple sclerosis: A 7-T imaging study.
Mult Scler. 2024 Jan 27:13524585231224681. doi: 10.1177/13524585231224681. PubMedAbstract available
HIRT J, Janiaud P, Dublin P, Nicoletti GJ, et al Use of pragmatic randomized trials in multiple sclerosis: A systematic overview.
Mult Scler. 2024 Jan 22:13524585231221938. doi: 10.1177/13524585231221938. PubMedAbstract available
CAMERLINGO S, Rubinstein F, Celia Ysrraelit M, Correale J, et al Clinical impact of gender and age at onset on disease trajectory in primary
progressive multiple sclerosis patients.
Mult Scler. 2024 Jan 21:13524585231219138. doi: 10.1177/13524585231219138. PubMedAbstract available
JEANTIN L, Januel E, Labauge P, Maillart E, et al COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from
2020 to 2022.
Mult Scler. 2024 Jan 21:13524585231218149. doi: 10.1177/13524585231218149. PubMedAbstract available
TENI FS, Machado A, Fink K, Gyllensten H, et al Recent trends in disease-modifying therapy use and associated sickness absence
and disability pension among people with multiple sclerosis in Sweden.
Mult Scler. 2024 Jan 19:13524585231225929. doi: 10.1177/13524585231225929. PubMedAbstract available
VIDAL-JORDANA A, Sastre-Garriga J, Tintore M, Rovira A, et al Optic nerve topography in multiple sclerosis diagnostic criteria: Existing
knowledge and future directions.
Mult Scler. 2024 Jan 19:13524585231225848. doi: 10.1177/13524585231225848. PubMedAbstract available
TOOROP AA, Noteboom S, Steenwijk MD, Gravendeel JW, et al Exploring the effects of extended interval dosing of natalizumab and drug
concentrations on brain atrophy in multiple sclerosis.
Mult Scler. 2024 Jan 18:13524585231225855. doi: 10.1177/13524585231225855. PubMedAbstract available
DAS J, Rog DJ, Middleton R, Rodgers JW, et al University education facilitates uptake of disease-modifying therapies for
multiple sclerosis: A community-based study using the UK MS Register.
Mult Scler. 2024 Jan 17:13524585231221411. doi: 10.1177/13524585231221411. PubMedAbstract available
PORTACCIO E, Iaffaldano P Maternal smoking and multiple sclerosis risk in offspring: A further clue of
prenatal environmental triggers.
Mult Scler. 2024 Jan 11:13524585231224667. doi: 10.1177/13524585231224667. PubMed
FRAMKE E, Thygesen LC, Malmborg M, Schou M, et al Risk of cardiovascular disease in patients with multiple sclerosis treated with
fingolimod compared to natalizumab: A nationwide cohort study of 2095 patients in
Denmark.
Mult Scler. 2024 Jan 11:13524585231221415. doi: 10.1177/13524585231221415. PubMedAbstract available
MOTYL J Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and
sensitive approaches beyond simple cut-offs.
Mult Scler. 2024 Jan 9:13524585231221409. doi: 10.1177/13524585231221409. PubMed
MORROW SA Response to letter to the editor "Advancing assessment of cognitive change in
multiple sclerosis: Seeking valid and sensitive approaches beyond simple
cut-offs".
Mult Scler. 2024 Jan 9:13524585231221412. doi: 10.1177/13524585231221412. PubMed
VENET M, Lepine A, Maarouf A, Biotti D, et al Control of disease activity with large extended-interval dosing of
rituximab/ocrelizumab in highly active pediatric multiple sclerosis.
Mult Scler. 2024 Jan 2:13524585231223069. doi: 10.1177/13524585231223069. PubMedAbstract available
WEINSHENKER BG MRI of the relevant domain should be performed to confirm whether clinical
symptoms represent an attack of NMOSD: Commentary.
Mult Scler. 2024;30:23-24. PubMed
CARNERO CONTENTTI E, Wingerchuk DM MRI of the relevant domain should be performed to confirm whether clinical
symptoms represent an attack of NMOSD: Yes.
Mult Scler. 2024;30:19-21. PubMed
MARIGNIER R, Cree BA MRI of the relevant domain should be performed to confirm whether clinical
symptoms represent an attack of NMOSD: No.
Mult Scler. 2024;30:21-23. PubMed
VAN LAETHEM D, Denissen S, Costers L, Descamps A, et al The Finger Dexterity Test: Validation study of a smartphone-based manual
dexterity assessment.
Mult Scler. 2024;30:121-130. PubMedAbstract available
HUGOS CL, Joos SK, Perumean-Chaney SE, Cutter GR, et al Stretching is not essential for managing MS spasticity: A randomized controlled
trial.
Mult Scler. 2024;30:89-102. PubMedAbstract available
DE GIER M, Beckerman H, Twisk JW, Knoop H, et al Effectiveness of a blended booster programme for the long-term outcome of
cognitive behavioural therapy for MS-related fatigue: A randomized controlled
trial.
Mult Scler. 2024;30:71-79. PubMedAbstract available
GUO RY, Wang WY, Huang JY, Jia Z, et al Deciphering prognostic indicators in AQP4-IgG-seropositive neuromyelitis optica
spectrum disorder: An integrative review of demographic and laboratory factors.
Mult Scler. 2024;30:7-15. PubMedAbstract available
WRIGHT SL, Thompson AJ Managing patients with late-onset neutropenia during treatment with ocrelizumab.
Mult Scler. 2024;30:134. PubMed
KOCH-HENRIKSEN NI, Thygesen LC, Sorensen PS, Magyari M, et al Using instrumental variables to correct for bias in real-world cohort studies of
the effects of disease-modifying treatment in MS.
Mult Scler. 2024;30:113-120. PubMedAbstract available
December 2023
PARCIAK T, Geys L, Helme A, van der Mei I, et al Introducing a core dataset for real-world data in multiple sclerosis registries
and cohorts: Recommendations from a global task force.
Mult Scler. 2023 Dec 23:13524585231216004. doi: 10.1177/13524585231216004. PubMedAbstract available
DOBSON R, Holden D, Vickaryous N, Bestwick J, et al A phase 2a open-label clinical trial to determine the effect of famciclovir on
EBV activity as measured by EBV shedding in the saliva of patients with multiple
sclerosis.
Mult Scler. 2023 Dec 22:13524585231215268. doi: 10.1177/13524585231215268. PubMedAbstract available
NAISMITH RT, Cohen JA, Bar-Or A, Comi G, et al Concurrent administration of serotonergic antidepressants and ozanimod in
participants with relapsing multiple sclerosis from the open-label extension
DAYBREAK trial.
Mult Scler. 2023 Dec 21:13524585231216854. doi: 10.1177/13524585231216854. PubMedAbstract available
TAZZA F, Schiavi S, Leveraro E, Cellerino M, et al Clinical and radiological correlates of apathy in multiple sclerosis.
Mult Scler. 2023 Dec 14:13524585231217918. doi: 10.1177/13524585231217918. PubMedAbstract available
DABOUL L, O'Donnell CM, Amin M, Rodrigues P, et al A multicenter pilot study evaluating simplified central vein assessment for the
diagnosis of multiple sclerosis.
Mult Scler. 2023 Dec 13:13524585231214360. doi: 10.1177/13524585231214360. PubMedAbstract available
DALLA COSTA G, Nos C, Zabalza A, Buron M, et al A wearable device perspective on the standard definitions of disability
progression in multiple sclerosis.
Mult Scler. 2023 Dec 12:13524585231214362. doi: 10.1177/13524585231214362. PubMedAbstract available
BRUCE JM, Cozart JS, Shook RP, Befort C, et al Modifying diet and exercise in multiple sclerosis (MoDEMS): A randomized
controlled trial for behavioral weight loss in adults with multiple sclerosis and
obesity.
Mult Scler. 2023;29:1860-1871. PubMedAbstract available
SACCO S, Virupakshaiah A, Papinutto N, Schoeps VA, et al Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from
myelin oligodendrocyte glycoprotein antibody-associated disease.
Mult Scler. 2023;29:1736-1747. PubMedAbstract available
LUBLIN FD Worsening MS-A reappraisal of how we characterize the MS disease course.
Mult Scler. 2023;29:1699-1700. PubMed
SAMADZADEH S, Olesen MN, Wirenfeldt M, Moller S, et al Microfibrillar-associated protein 4 as a potential marker of acute relapse in
inflammatory demyelinating diseases of the central nervous system: Pathological
and clinical aspects.
Mult Scler. 2023;29:1721-1735. PubMedAbstract available
PROSCHMANN U, Mueller-Enz M, Woopen C, Katoul Al Rahbani G, et al Differential effects of selective versus unselective sphingosine 1-phosphate
receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination.
Mult Scler. 2023;29:1849-1859. PubMedAbstract available
MORROW SA, Weinstock ZL, Mirmosayyeb O, Conway D, et al Detecting isolated cognitive relapses in persons with MS.
Mult Scler. 2023;29:1786-1794. PubMedAbstract available
ENGELS D, Havla J, Forderreuther S, Kumpfel T, et al Therapy challenges for NMOSD in a patient with HIV.
Mult Scler. 2023;29:1872-1875. PubMedAbstract available
November 2023
MATTIESING RM, Kramer E, Strijbis EM, Brouwer I, et al Disease progression in the first 5 years of treatment in multiple sclerosis:
Predictive value of early brain and lesion volume changes.
Mult Scler. 2023 Nov 29:13524585231212879. doi: 10.1177/13524585231212879. PubMedAbstract available
ZHAO T, Taylor BV, Campbell JA, Palmer AJ, et al The disease-modifying therapy utilisation and cost trend for multiple sclerosis
in Australia between 2013 and 2022.
Mult Scler. 2023 Nov 24:13524585231213230. doi: 10.1177/13524585231213230. PubMedAbstract available
MONTEIRO IR, Moccia M Mobile health interventions in multiple sclerosis: Bringing empowerment into
clinical practice.
Mult Scler. 2023 Nov 20:13524585231214879. doi: 10.1177/13524585231214879. PubMed
CASTANO-AMORES C, Nieto-Gomez P The crossroads of multiple sclerosis and cancer: Urgent call for clinical
direction.
Mult Scler. 2023 Nov 20:13524585231214171. doi: 10.1177/13524585231214171. PubMed
LADAKIS DC, Reyes-Mantilla MI, Gadani SP, Mace JW, et al Serum macrophage migration inhibitory factor levels predict brain atrophy in
people with primary progressive multiple sclerosis.
Mult Scler. 2023 Nov 20:13524585231213164. doi: 10.1177/13524585231213164. PubMedAbstract available
NIELSEN NM, Frisch M, Gortz S, Stenager E, et al Smoking during pregnancy and risk of multiple sclerosis in offspring and mother:
A Danish nationwide register-based cohort study.
Mult Scler. 2023 Nov 19:13524585231208310. doi: 10.1177/13524585231208310. PubMedAbstract available
BROCHET B, Solari A, Lechner-Scott J, Piehl F, et al Improvements in quality of life over 2 years with cladribine tablets in people
with relapsing multiple sclerosis: The CLARIFY-MS study.
Mult Scler. 2023 Nov 18:13524585231205962. doi: 10.1177/13524585231205962. PubMedAbstract available
NICHOLSON S, Russo AW, Brewer K, Bien H, et al The effect of ibudilast on thalamic volume in progressive multiple sclerosis.
Mult Scler. 2023 Nov 10:13524585231204710. doi: 10.1177/13524585231204710. PubMedAbstract available
BOU RJEILY N, Fitzgerald KC, Mowry EM Extended interval dosing of ocrelizumab in patients with multiple sclerosis is
not associated with meaningful differences in disease activity.
Mult Scler. 2023 Nov 9:13524585231208311. doi: 10.1177/13524585231208311. PubMedAbstract available
AMEZCUA L, Robers MV, Soneji D, Manouvakhova O, et al Inclusion of optic neuritis in dissemination in space improves the performance of
McDonald 2017 criteria in Hispanic people with suspected multiple sclerosis.
Mult Scler. 2023 Nov 9:13524585231209016. doi: 10.1177/13524585231209016. PubMedAbstract available
VAN KEMPEN ZL, van Dam KP, Keijser JB, Stalman EW, et al Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and
infection in MS patients on fingolimod.
Mult Scler. 2023 Nov 9:13524585231207761. doi: 10.1177/13524585231207761. PubMedAbstract available
ZICCARDI S, Fuchs T, Dwyer MG, Zivadinov R, et al Cognitive phenotypes predict response to restorative cognitive rehabilitation in
multiple sclerosis.
Mult Scler. 2023 Nov 9:13524585231208331. doi: 10.1177/13524585231208331. PubMedAbstract available
FEINSTEIN A The CogEx trial - Cognitive rehabilitation and aerobic exercise for cognitive
impairment in people with progressive multiple sclerosis: A randomised, blinded,
sham-controlled trial.
Mult Scler. 2023 Nov 2:13524585231210178. doi: 10.1177/13524585231210178. PubMed
CHASE E, Chen V, Martin K, Lane M, et al A low-fat diet improves fatigue in multiple sclerosis: Results from a randomized
controlled trial.
Mult Scler. 2023;29:1659-1675. PubMedAbstract available
WEINSTOCK ZL, Jaworski M 3rd, Dwyer MG, Jakimovski D, et al Auditory Test of Processing Speed: Preliminary validation of a smartphone-based
test of mental speed.
Mult Scler. 2023;29:1646-1658. PubMedAbstract available
WISHART M, Everest MR, Morrow SA, Rose J, et al Establishing the consistency of a voice recognition symbol digit modalities test
analogue.
Mult Scler. 2023;29:1676-1679. PubMedAbstract available
BOCCIA VD, Saitta L, Inglese M, Lapucci C, et al Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an
RRMS antiCD20-treated patient.
Mult Scler. 2023;29:1688-1692. PubMedAbstract available
October 2023
ONTANEDA D, Amezcua L Re-thinking race and geography in multiple sclerosis.
Mult Scler. 2023 Oct 31:13524585231205969. doi: 10.1177/13524585231205969. PubMed
SINGER BA, Arnold DL, Drulovic J, Freedman MS, et al Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final
safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Mult Scler. 2023 Oct 31:13524585231205708. doi: 10.1177/13524585231205708. PubMedAbstract available
HEESEN C, Berger T, Riemann-Lorenz K, Krause N, et al Mobile health interventions in multiple sclerosis: A systematic review.
Mult Scler. 2023 Oct 28:13524585231201089. doi: 10.1177/13524585231201089. PubMedAbstract available
PORWAL MH, Obeidat AZ A closer look at reported colitis in association with multiple sclerosis
treatments.
Mult Scler. 2023 Oct 28:13524585231205964. doi: 10.1177/13524585231205964. PubMed
LEARMONTH YC, P Herring M, Russell DI, Pilutti LA, et al Safety of exercise training in multiple sclerosis: An updated systematic review
and meta-analysis.
Mult Scler. 2023 Oct 26:13524585231204459. doi: 10.1177/13524585231204459. PubMedAbstract available
RAMARI C, Awadia Z, Bansi J, Casey B, et al The MoxFo initiative - outcomes: Outcome measures in studies of exercise training
in multiple sclerosis; scoping review of reviews and classification according to
the ICF framework.
Mult Scler. 2023 Oct 26:13524585231204451. doi: 10.1177/13524585231204451. PubMedAbstract available
DALGAS U, Riemenschneider M, Gold SM, Kalron A, et al The MoXFo initiative - study design: Considerations related to study design and
methodology in exercise research for people with multiple sclerosis.
Mult Scler. 2023 Oct 26:13524585231204456. doi: 10.1177/13524585231204456. PubMedAbstract available
MANSOUBI M, Learmonth YC, Mayo N, Collet J, et al The MoXFo Initiative: Using consensus methodology to move forward towards
internationally shared vocabulary in multiple sclerosis exercise research.
Mult Scler. 2023 Oct 26:13524585231204460. doi: 10.1177/13524585231204460. PubMedAbstract available
ROSENKRANZ SC, Ploughman M, Hvid LG, Zimmer P, et al The MoxFo initiative-Mechanisms of action: Biomarkers in multiple sclerosis
exercise studies.
Mult Scler. 2023 Oct 26:13524585231204453. doi: 10.1177/13524585231204453. PubMedAbstract available
MOTL RW, Casey B, Learmonth YC, Latimer-Cheung A, et al The MoXFo initiative - adherence: Exercise adherence, compliance and
sustainability among people with multiple sclerosis: An overview and roadmap for
research.
Mult Scler. 2023 Oct 26:13524585231204446. doi: 10.1177/13524585231204446. PubMedAbstract available
ZHANG Y, Atkinson J, Burd CE, Graves J, et al Biological aging in multiple sclerosis.
Mult Scler. 2023 Oct 25:13524585231204122. doi: 10.1177/13524585231204122. PubMedAbstract available
BEREK K, Hegen H, Auer M, Barket R, et al Odour discrimination and identification as a biomarker of long-term disability
worsening in multiple sclerosis.
Mult Scler. 2023 Oct 18:13524585231201093. doi: 10.1177/13524585231201093. PubMedAbstract available
KOCH MW, Moral E, Brieva L, Mostert J, et al Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the
CombiRx dataset.
Mult Scler. 2023 Oct 13:13524585231202320. doi: 10.1177/13524585231202320. PubMedAbstract available
DARVISHI S, Donnachie E, Gasperi C, Hapfelmeier A, et al Vaccination frequency in people newly diagnosed with multiple sclerosis.
Mult Scler. 2023 Oct 13:13524585231199084. doi: 10.1177/13524585231199084. PubMedAbstract available
REYES S, Otero-Romero S Rethinking vaccination in multiple sclerosis: The way forward.
Mult Scler. 2023 Oct 3:13524585231204126. doi: 10.1177/13524585231204126. PubMed
LAPUCCI C, Boccia VD, Sirito T, Cellerino M, et al Safety of anti-varicella zoster virus vaccination in patients with multiple
sclerosis treated with natalizumab: A case series.
Mult Scler. 2023 Oct 3:13524585231204121. doi: 10.1177/13524585231204121. PubMedAbstract available
TIEPPO EMS, Silva GD, Silva TFFD, Araujo RS, et al Misdiagnosis in multiple sclerosis in a Brazilian reference center: Clinical,
radiological, laboratory profile and failures in the diagnostic process-Cohort
study.
Mult Scler. 2023 Oct 3:13524585231199323. doi: 10.1177/13524585231199323. PubMedAbstract available
JACOBER SLS, Disanto G, Sacco R, Meng D, et al Interplay between age and disease-modifying treatments in influencing infection
risk in multiple sclerosis.
Mult Scler. 2023 Oct 3:13524585231199820. doi: 10.1177/13524585231199820. PubMedAbstract available
UHER T, Adzima A, Srpova B, Noskova L, et al Diagnostic delay of multiple sclerosis: prevalence, determinants and
consequences.
Mult Scler. 2023;29. PubMedAbstract available
WU Y, Geraldes R, Jurynczyk M, Palace J, et al Double-negative neuromyelitis optica spectrum disorder.
Mult Scler. 2023;29. PubMedAbstract available
THOMPSON AJ, Moccia M, Amato MP, Calabresi PA, et al Do the current MS clinical course descriptors need to change and if so how? A
survey of the MS community.
Mult Scler. 2023;29. PubMedAbstract available
September 2023
ANDERSON JR, Fitzgerald KC, Murrough JW, Katz Sand IB, et al Depression symptoms and cognition in multiple sclerosis: Longitudinal evidence of
a specific link to executive control.
Mult Scler. 2023 Sep 29:13524585231198746. doi: 10.1177/13524585231198746. PubMedAbstract available
CERDA-FUERTES N, Stoessel M, Mickeliunas G, Pless S, et al Optical coherence tomography versus other biomarkers: Associations with physical
and cognitive disability in multiple sclerosis.
Mult Scler. 2023 Sep 29:13524585231198760. doi: 10.1177/13524585231198760. PubMedAbstract available
VERCELLINO M, Costantini G, Cogoni M, Lequio L, et al Association of MRI leptomeningeal enhancement with disability worsening in
progressive multiple sclerosis: A clinical and post-mortem study.
Mult Scler. 2023 Sep 23:13524585231199031. doi: 10.1177/13524585231199031. PubMedAbstract available
FREEDMAN DE, Krysko KM, Feinstein A Intimate partner violence and multiple sclerosis.
Mult Scler. 2023 Sep 21:13524585231197926. doi: 10.1177/13524585231197926. PubMedAbstract available
CARVAJAL R, Tur C, Martinez-Gomez X, Bollo L, et al A single-dose strategy for immunization with live attenuated vaccines is an
effective option before treatment initiation in multiple sclerosis patients.
Mult Scler. 2023 Sep 20:13524585231200303. doi: 10.1177/13524585231200303. PubMedAbstract available
MORALES-RODRIGUEZ D, Anderson A, Nylander A, Hsu S, et al Well-being at midlife: Correlates of mental health in ambulatory menopausal women
with multiple sclerosis.
Mult Scler. 2023 Sep 16:13524585231197056. doi: 10.1177/13524585231197056. PubMedAbstract available
KRAJNC N, Schmidbauer V, Leinkauf J, Haider L, et al Paramagnetic rim lesions lead to pronounced diffuse periplaque white matter
damage in multiple sclerosis.
Mult Scler. 2023 Sep 15:13524585231197954. doi: 10.1177/13524585231197954. PubMedAbstract available
BOSE G, Healy BC, Barro C, Moreira Ferreira VF, et al Accuracy of serum neurofilament light to identify contrast-enhancing lesions in
multiple sclerosis.
Mult Scler. 2023 Sep 15:13524585231198751. doi: 10.1177/13524585231198751. PubMedAbstract available
MARTIN SJ, Brand-Arzamendi K, Saab G, Muccilli A, et al GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple
sclerosis.
Mult Scler. 2023 Sep 12:13524585231195861. doi: 10.1177/13524585231195861. PubMedAbstract available
MOGHAVEM N, Castaneda GDR, Chatfield AJ, Amezcua L, et al The impact of medical insurance on health care access and quality for people with
multiple sclerosis in the United States: A scoping review.
Mult Scler. 2023 Sep 12:13524585231197275. doi: 10.1177/13524585231197275. PubMedAbstract available
WANG Y, Bou Rjeily N, Koshorek J, Grkovski R, et al Clinical and radiologic characteristics associated with multiple sclerosis
misdiagnosis at a tertiary referral center in the United States.
Mult Scler. 2023 Sep 12:13524585231196795. doi: 10.1177/13524585231196795. PubMedAbstract available
BRUNO A, Buttari F, Dolcetti E, Azzolini F, et al Distinct intrathecal inflammatory signatures following relapse and anti-COVID-19
mRNA vaccination in multiple sclerosis.
Mult Scler. 2023 Sep 12:13524585231197928. doi: 10.1177/13524585231197928. PubMedAbstract available
HAUSER SL, Zielman R, Das Gupta A, Xi J, et al Efficacy and safety of four-year ofatumumab treatment in relapsing multiple
sclerosis: The ALITHIOS open-label extension.
Mult Scler. 2023 Sep 11:13524585231195346. doi: 10.1177/13524585231195346. PubMedAbstract available
DEJONGE SR, DuBose NG, Pilutti LA, Motl RW, et al Arterial stiffness in persons with multiple sclerosis and controls: Does aerobic
fitness account for group differences?
Mult Scler. 2023 Sep 11:13524585231199030. doi: 10.1177/13524585231199030. PubMedAbstract available
GABRIELLI M, Verderio C Exosomal profiling should be used to monitor disease activity in MS patients:
Commentary.
Mult Scler. 2023 Sep 7:13524585231195858. doi: 10.1177/13524585231195858. PubMed
DELTOMBE M, van Pesch V Exosomal profiling should be used to monitor disease activity in MS patients: No.
Mult Scler. 2023 Sep 7:13524585231195859. doi: 10.1177/13524585231195859. PubMed
MYCKO MP Exosomal profiling should be used to monitor disease activity in MS patients:
Yes.
Mult Scler. 2023 Sep 7:13524585231195860. doi: 10.1177/13524585231195860. PubMed
CARNERO CONTENTTI E Rectifying global inequities in neuromyelitis optica diagnosis and treatment: A
critical view from Latin America.
Mult Scler. 2023;29:1347-1348. PubMed
BERHANU D, Leal Rato M, Messina S, Leite MI, et al The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD.
Mult Scler. 2023;29:1250-1256. PubMedAbstract available
CARNERO CONTENTTI E, Lopez PA, Tkachuk V, Vrech C, et al Frequency of new asymptomatic MRI lesions during attacks and follow-up of
patients with NMOSD in a real-world setting.
Mult Scler. 2023;29:1240-1249. PubMedAbstract available